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ABSTRACT 
 
The discovery of nitric oxide (NO), a toxic gas, as a gasotransmitter produced by 
mammalian cells has generated interest in other gases that may act as signaling 
molecules. One of those gases is hydrogen sulfide (H2S), produced by the transsulfuration 
enzymes CBS and CSE, which has been postulated to be a gasotransmitter like NO. We 
developed a microplate-based colourimetric assay for free H2S gas. Solutions of 
dissolved H2S spontaneously release gaseous H2S. In our assay gaseous H2S is released 
from solution, and reacts with silver embedded on the underside of a microplate cover, 
forming Ag2S, which can be quantified by absorbance. Using this assay the kinetic 
parameters of CSE were measured, as was H2S production from mouse liver 
homogenates. H2S has been postulated to signal through modification of cysteine residues 
on proteins (S-sulfuration), and the first protein shown to be S-sulfurated was GAPDH. 
We reinvestigated the H2S-induced S-sulfuration of GAPDH, and the effect of the initial 
redox state of the enzyme on S-sulfuration. Contrary to the previous literature results, we 
found that Cys 156 was S-sulfurated, and not the active site Cys 152. S-sulfuration of Cys 
156 caused a decrease in enzymatic activity. It was possible to S-sulfurate Cys 152 in a 
C156S mutant of GAPDH, which caused a decrease in enzymatic activity. We propose a 
new role for Cys 156 as a protective thiol for Cys 152. Our results also show that 
polysulfides, which can be generated from H2S, are a stronger S-sulfurating agent than 
NaSH. When analyzing protein modifications by mass spectrometry, the tryptic peptide 
of interest may be in low stoichiometry compared to the rest of the digest. This may 
necessitate sample enrichment methods. We tested gold nanoparticles (AuNPs) as an 
enrichment method for sulfur-containing peptides. AuNPs showed some affinity for 
sulfur-containing peptides, and may be used in studies of protein thiols by mass 
spectrometry. NO has been shown to be an important mediator of wound healing, and 
NO-releasing materials may be used as wound dressings. We started the development of 
a chitosan-based NO-releasing wound dressing, which releases NO from nitrite (NO2
-) by 
copper ions. All major components in our design, chitosan, copper, and NO, have been 
previously shown to have therapeutic properties. 
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CHAPTER 1 
 
GENERAL INTRODUCTION 
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1.1 Hydrogen Sulfide 
1.1.1 Introduction and Biological Functions of H2S 
Hydrogen sulfide (H2S) has long been known to be a toxic pollutant produced from 
decomposition of organic matter and from various industrial processes. The toxicity of 
H2S has been known for over a century, and its toxic effects observed for longer than 
that. The production of small amounts of H2S in mammalian tissues has been known for 
decades [1], although the physiological implications of this were not explored until the 
late 1990’s. The identification of nitric oxide (NO) as the endothelium-derived relaxing 
factor (EDRF) in the late 1980’s likely generated additional interest in other gases 
produced in the body that may act as signaling molecules [2]. In the late 1990’s and early 
2000’s experiments showed alteration in H2S homeostasis affected important 
physiological processes [3, 4]. This has led to the postulation that H2S is a physiological 
gasotransmitter [4, 5], like NO and CO, which is synthesized at low levels in tissues to 
fulfill a signaling function. Since then the interest in H2S research has grown 
tremendously, and subsequent studies have revealed effects of H2S in almost every organ 
system. 
One of the earliest studies on H2S showed exogenous H2S was, similarly to NO, 
able to cause vascular smooth muscle relaxation [4]. The mechanism of vascular smooth 
muscle relaxation was discovered to be through opening of ATP-sensitive potassium 
channels (KATP) [6]; the mechanism was later hypothesized to be S-sulfuration 
(sulfhydration) of the KATP channel SUR subunit [7, 8]. Since then H2S has been shown 
to act as a vasodilator in many different types of vascular tissues [9-19]. These 
experiments generally involve the application of exogenous H2S to isolated blood vessels. 
Although KATP channels were hypothesized to be the molecular targets of H2S, other 
pathways have been proposed as well, including voltage-gated Ca2+ channels [13], Cl-
/HCO3
- [14, 15], Big Potassium (BKCa) channels [16], potassium voltage-gated channels  
(KCNQ) [17], L-type Ca2+ channels and K channels (but not KATP, KCa, KV, or Kir 
subtypes) [18], and calcium-activated chloride channels (CaCCs) [19]. The type of blood 
vessel as well as the species may determine the exact mechanism of vasorelaxation, and 
both endothelium-dependent and endothelium-independent types of vasorelaxation have 
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been observed in the literature [18]. Paradoxically it has also been reported that H2S 
causes vasoconstriction [20-22]; this process has been determined to be O2-dependent. At 
low O2 concentrations H2S acts as a vasodilator, while at higher than physiological O2 
concentrations H2S acts as a vasoconstrictor [20]. It has been hypothesized that H2S acts 
as an O2 sensor and controls hypoxic pulmonary vasoconstriction [23, 24], although this 
hypothesis has been recently questioned [25]. One of the most widely-cited lines of 
evidence is that CSE-knockout mice were found to be hypertensive, displayed a 
diminished endothelium-dependent vasorelaxation, and had lower tissue levels of H2S 
[26]. This has not been independently verified since an independent study on CSE 
knockout mice showed the mice were normotensive [27]. H2S has also been proposed to 
be endothelium derived hyperpolarizing factor (EDHF) [8, 28-30]. EDHF is a nitric oxide 
synthase and cyclooxygenase independent vascular relaxation pathway [31]. EDHF is 
dominant is small blood vessels, while NO is dominant in large ones. Although H2S has 
been proposed to be EDHF, many chemical species have been proposed to be the EDHF 
including epoxyeicosatrienoic acids, H2O2, K
+, and C-type natriuretic peptide [32]. It is 
likely EDHF represents a mechanism of smooth muscle hyperpolarization, which can be 
initiated by many, and not a single, chemical species. 
H2S can affect ion channels and numerous functions of H2S have been postulated 
in the nervous system. The two main proposed roles of H2S in the nervous system are 
neuromodulation and neuroprotection [33]. One of the first studies on the biological 
functions of endogenous H2S by Abe and Kimura in 1996 found that H2S enhances N-
methyl-D-aspartate (NMDA) receptor mediated current and enhances neuronal long term 
potentiation [3]. H2S facilitates long term potentiation by increasing Ca
2+ uptake in 
astrocytes by activation of transient receptor potential cation member A1 (TRPA1) 
channels [34, 35]. Astrocytes then release D-serine into the synapse which enhances the 
activity of NMDA receptors [36]. Polysulfides were ~300 times more effective at 
increasing Ca2+ uptake than H2S [34]. H2S also has the ability to modulate nociception 
(pain sensing) [37]. H2S causes hyperalgesia (increased sensitivity to pain) in animal 
models by stimulating CaV3.2 T-type Ca
2+ channels [38-40] which are present in nerve 
endings [41]. The mechanism is due to H2S reacting with endogenous Zn
2+ ions which 
endogenously inhibit T-type Ca2+ channels [42-44]. H2S also acts as a pro-nociceptor by 
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activating TRPA1, a channel expressed in sensory neurons which responds to 
temperature and natural chemical irritants, among other stimuli [45-47]. 
 H2S has been linked to major neurological diseases Alzheimer’s disease, and 
Parkinson’s disease. Elevated plasma homocysteine level has been associated with 
Alzheimer’s disease [48], suggesting the H2S-producing enzyme CBS, which also 
metabolizes homocysteine, is involved in the pathogenesis of the disease [49]. Decreased 
levels of H2S have been detected by GC in brain autopsy samples from Alzheimer’s 
disease patients [50]. The levels of CBS in Alzheimer’s brain were unchanged, however 
the levels of CBS activator S-adenosyl-L-methionine (SAM) were lower, and levels of 
homocysteine were higher. NaSH was able to reduce amyloid beta protein levels in SH-
SY5Y cells by inhibiting the γ-secretase protein [51]. In a rat model of Alzheimer’s 
disease treatment with NaSH or spa-water rich with H2S (Tabiano water) improved 
learning and memory [52]. The treatment lowered the size of amyloid beta plaques and 
increased the amount of healthy neurons. Similarly in a mouse model of Alzheimer’s 
disease treatment of NaSH improved spatial learning and memory and lessened plaque 
formation [53].  
Elevated plasma homocysteine levels have been also associated with severity of 
Parkinson’s disease [54, 55], a disease characterized by the loss of dopaminergic neurons 
in the brain. NaSH was able to reduce 1-methyl-4-phenylpyridinium ion (MPP+) induced 
cytotoxicity and apoptosis in PC12 cells, a cell line commonly used to study Parkinson’s 
disease [56]. NaSH was also able to reduce cytotoxicity and apoptosis in SH-SY5Y cells 
(a type of human neuroblastoma cell line) treated with rotenone, a pesticide which can 
degrade dopaminergic neurons [57], and in SH-SY5Y cells treated with 6-
hydroxydopamine (6-OHDA), a dopaminergic neurotoxin [58]. Various H2S-releasing L-
DOPA derivatives have been developed and tested in cell [59], and animal models of 
Parkinson’s disease [60]. Inhaled H2S has also been shown to be neuroprotective in a 
mouse model of Parkinson’s disease [61]. H2S has also been shown to be neuroprotective 
against lipopolysaccharide (LPS) induced inflammation [62], and glutamate toxicity [63, 
64].  
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Although low concentrations of H2S have been demonstrated to have therapeutic 
properties in disease models, it is well-known that H2S is a toxic gas which can be lethal 
at higher concentrations. The concentration of H2S is larger determinant of toxicity rather 
than the length of exposure [65]. In animal studies using rats, LC50 for 2 h of exposure 
was 587 ppm, while LC50 for 6 h of exposure was 335 ppm. The symptoms associated 
with H2S toxicity are eye irritation, olfactory paralysis, pulmonary edema, and abrupt loss 
of consciousness [66]. Perhaps the most famous symptom of H2S toxicity is olfactory 
paralysis. The human nose is extremely sensitive to H2S at low concentrations and can 
smell 0.01-0.3 ppm H2S, while at higher concentrations of ~100 ppm H2S causes 
olfactory paralysis and the characteristic H2S smell disappears [66]. Olfactory paralysis 
occurs due to neurotoxicity of H2S towards olfactory bulb and fibers [67], and a 
permanent decrease in the sense of smell has been reported in patients who recovered 
from H2S poisoning [68]. Eye and lung irritation can occur at 20-50 ppm H2S, pulmonary 
edema at 250-500 ppm, sudden loss of consciousness at 500 ppm and prolonged exposure 
at 500 ppm may cause death [66]. The mechanism of H2S toxicity is similar to that of 
cyanide; both cyanide and H2S inhibit cellular respiration by inhibiting mitochondrial 
cytochrome c oxidase [69]. When exposed to 80 ppm H2S mice exhibit a reduced 
metabolic rate and enter a state of suspended animation [70]. In this state core body 
temperature dropped to 2 °C above ambient temperature and breathing rate dropped from 
120 breaths per minute to 10. When brought out of suspended animation the mice 
exhibited no behavioral or functional changes. Similarly oil patch workers who lost 
consciousness due to high but transient H2S concentrations experienced rapid recovery 
[66]. 
1.1.2 H2S-Producing Enzymes 
H2S may be produced enzymatically by cystathionine β-synthase (CBS), cystathionine γ-
lyase (CSE), or through the collective action of enzymes cysteine aminotransferase 
(CAT) and 3-mercaptopyruvate sulfurtransferase (3-MST) [1]. As their names suggest 
the enzymes are not exclusively H2S-producing enzymes, and perform other important 
functions in addition to H2S production. CBS and CSE are PLP (pyridoxal phosphate) 
dependent enzymes involved in the reverse transsulfuration pathway [1]. The reverse 
 6 
 
transsulfuration pathway is responsible for the conversion of homocysteine, which can be 
produced from methionine, to cysteine, and as a result cysteine is a non-essential amino 
acid for humans [71-73]. CBS catalyzes the first step of the transsulfuration pathway, 
which is the formation of cystathionine by linking homocysteine and serine (Figure 1.1.2-
1) [74, 75]. CSE catalyzes the second step of the transsulfuration pathway, which is the 
cleavage of cystathionine to form α-ketobutyrate, cysteine, and ammonia (Figure 1.1.2-
1). Due to low substrate specificity CBS and CSE can also catalyze a number of other 
reactions where H2S is formed as a byproduct (Figures 1.1.2-2 & 1.1.2-3) [74]. The 
second reaction catalyzed by CBS can metabolize homocysteine through a condensation 
reaction with cysteine, generating cystathionine and H2S. The third and fourth reactions 
catalyzed by CBS are the conversion of cysteine to serine and H2S, and condensation of 
cysteine to form lanthionine and H2S. CSE catalyzes the condensation of cysteine to 
lanthionine and H2S. CSE can metabolize cysteine to pyruvate, ammonia, and H2S. CSE 
catalyzes the condensation of homocysteine to form homolanthionine and H2S. CSE 
catalyzes the condensations of cysteine and homocysteine form its transsulfuration 
substrate cystathionine and H2S. CSE can also catalyze homocysteine to form α-
ketobutyrate, H2S, and ammonia. The transsulfuration pathway plays an important role in 
catabolizing homocysteine [76], which is a toxic metabolite, and maintaining glutathione 
redox status by generating cysteine, which can be incorporated into GSH [76, 77]. 
Lanthionines are also starting to be considered neuroprotective molecules in the nervous 
system [76, 78]. CBS and CSE can also use cystine (cysteine disulfide) as a substrate to 
produce cysteine persulfides (Cys-SSH) [79, 80]. Cysteine persulfides can react with 
reduced glutathione to form glutathione persulfide, and may S-sulfurate proteins. 
Cysteine persulfides and glutathione persulfides have also been detected in vivo [79], 
although their physiological significance has not yet been explored. In H2S research, the 
biological effects due to alterations in CBS and CSE homeostasis are generally 
considered to be solely H2S-related. 
 The human CBS KM value for condensation of serine and homocysteine to form 
cystathionine is 2.76 mM [74]. The human CBS KM values for H2S producing reactions; 
conversion cysteine to serine, condensation of cysteine to lanthionine, and condensation 
of cysteine and homocysteine to cystathionine are 6.8 mM. The human CSE KM value for 
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conversion of cystathionine to cysteine is 0.5 mM, while the KM value for H2S generation 
from cysteine is 2.75 mM [81]. Cytosol cystathionine and cysteine concentrations are 
estimated at 10 µM and 100 µM respectively [74]. The large KM values for CBS and 
CSE, compared to substrate concentrations, indicate activity is highly dependent on 
substrate concentrations. CSE is more efficient at catalyzing its transsulfuration substrate, 
cystathionine, than H2S production from cysteine. The catalytic efficiency (kcat/KM) of 
CSE for cystathionine catabolism is 1.5 x 104 M-1 s-1, while the catalytic efficiency of 
CSE for H2S production from cysteine is 1.5 x 10
2 M-1 s-1 [81]. Cysteine is the most 
commonly used substrate added to cells or lysates in order to stimulate H2S production. 
 CBS is a homotetramer, each subunit is 63 kDa [82]. CBS contains a 70 amino 
acid length N-terminal heme domain, followed by a PLP-binding site and catalytic core, 
and a C-terminal regulatory domain [83]. The catalytic core includes a CXXC domain. 
Deletion of the heme domain results in a loss of sensitivity of the enzyme to titanium 
citrate [84], leading to a hypothesis that CBS heme acts as a redox sensor [84, 85]. CBS 
activity can also be inhibited by CO or NO binding to CBS heme [86-88]; suggesting 
CBS is regulated by CO and NO. Deletion of CBS heme domain reduces activity by 
~40%; however the enzyme retains the PLP binding ability [89]. The regulatory domain 
contains a binding site for the allosteric cofactor S-adenosylmethionine (AdoMet) [90]. 
CSE is also a PLP-dependent homotetramer; each subunit is 44.5 kDa [91]. 
 Initially CBS has been described to be localized in the brain and the nervous 
system, while CSE localized to the circulatory system and peripheral tissue [92]. CBS is 
highly expressed in the brain [3], while CSE is highly expressed in the liver and kidneys 
[93]. However a clear tissue division may not exist [92], and most tissues have an intact 
reverse transsulfuration pathway, meaning both CBS and CSE are present [94]. The 
relative quantities of CBS and CSE do vary and tissues may have a dominant H2S-
producing enzyme; for example CSE protein levels are ~60 fold higher than CBS in 
mouse liver, and ~20 fold higher in mouse kidney [75]. It has been suggested CSE is 
absent in the brain since it is undetectable by western blotting [95], however the 
conversion of [35S]-methionine to [35S]-cysteine was observed in cultured human 
neurons, murine neurons, murine astrocytes and mouse brain slices [93, 94], suggesting 
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an intact transsulfuration pathway. CSE activity was also 100 fold higher in human brain 
than in mouse brain [96]; animal models may not always be an accurate representation of 
human physiology. 
 Mutations in CBS can cause severe hereditary hyperhomocysteinemia [97]. 
Elevated homocysteine levels in circulation are associated with major diseases including 
cardiovascular disease [98], and Alzheimer’s disease [48]. Homozygous CBS knockout 
in mice is lethal; CBS knockout mice suffered from growth retardation, and died within 5 
weeks of birth [99]. This is most likely due to inability to metabolize homocysteine rather 
than H2S-related changes since homozygous CBS knockout mice had ~40 fold the normal 
plasma homocysteine levels [99]. CSE knockout mice display hypertension [26], 
although an independent CSE knockout mice study found mice were normotensive [27]. 
CSE knockout mice also required dietary cysteine to protect against lethal myopathy, and 
had a higher susceptibility to oxidative injury [27]. Mutations in CSE are very rare, but 
may cause genetic cystathioninuria, which is characterized by an abnormal level of 
plasma cystathionine [91, 100, 101]. 
 CBS and CSE activity in cell culture experiments may be modulated by enzyme 
inhibitors. The most commonly used inhibitors are DL-propargylglycine (PAG), β-
cyanoalanine (BCA), and aminooxyacetic acid (AOAA), which target the PLP binding 
site of CBS and CSE. PAG and BCA have been described in the literature as specific 
inhibitors of CSE, while AOAA has been described as a specific inhibitor of CBS. 
Although commonly described as specific inhibitors of CBS and CSE, PAG, BCA, and 
AOAA display many non-specific effects, as reviewed in detail by Whiteman et al. [92]. 
Since they target the PLP binding site, CBS and CSE inhibitors inhibit other PLP-
dependent enzymes. PAG, BCA, and AOAA are used in high millimolar concentrations 
and have been used in other research fields as “specific” inhibitors of other physiological 
processes [92]. It has also been shown that AOAA is a more powerful inhibitor of CSE 
rather than CBS [102]. The lack of specific inhibitors of CBS and CSE make it difficult 
to study their functions. 
 Another pathway of H2S production is through cysteine aminotransferase (CAT) 
and 3-mercaptopyruvate sulfurtransferase (3-MST) [1]. 3-MST is also known as tRNA 
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thiouridine modification protein (TUM1) and two splice variants have been discovered 
with molecular masses of 35.4 kDa and 33.3 kDa [103]. CAT/3-MST is less widely-
studied than CBS and CSE. CAT catabolizes cysteine by reaction with α-ketoglutarate to 
form 3-mercaptopyruvate (3-MP) and glutamate (Figure 1.1.2-4) [104]. 3-MST transfers 
the thiol from 3-mercaptopyruvate to an acceptor, which can be another thiol, forming a 
persulfide, or to cyanide, to form the less toxic thiocyanate [105] (Figure 1.1.2-4). This 
means reducing agents are required to liberate the sulfide from persulfides [1], and 3-
MST has been hypothesized to generate H2S for storage [106]. The crystal structure of 3-
MST revealed a complex with a Cys 248 persulfide and pyruvate, suggesting 3-MST is 
the initial thiol acceptor from 3-MP, although the exact reaction mechanism has not yet 
been elucidated [107]. The maximum enzymatic activity of 3-MST occurs in alkaline 
conditions [1, 107]. The KM values for 3-MST using 3-MP as a substrate have been 
reported as 1.2 mM using 2-mercaptoethanol as a sulfur acceptor [108], and 4.5 mM 
without a sulfur acceptor [109]. Yadav et al. reported KM values for 3-MST using 3-MP 
as a substrate using various sulfur acceptors; KM values ranged from 20 µM to 350 µM 
depending on the acceptor [107]. CAT/3-MST pathway has been discovered to produce 
H2S in the brain [106], and the vascular endothelium [110]. 3-MST has been shown to be 
localized in the mitochondria and the cytoplasm [103, 111]. In 1992, cysteine 
concentration in rat liver mitochondria has been determined to be ~0.7-1.0 mM [112]. 
Based on enzyme KM values and cellular substrate concentrations the CAT/3-MST 
pathway in the mitochondria might be the only H2S-producing system where H2S 
production might be favoured over other reactions [94]. A more recent study found the 
mitochondrial cysteine concentration in mouse SMCs to be 177.5 ± 5.8 µM [113]. 
Although high concentrations of H2S can inhibit mitochondrial electron transport by 
complex IV inhibition, low concentrations have been shown to stimulate mitochondrial 
electron transport by donating electrons to complex II through sulfide quinone reductase 
(SQR) [114]. Since 3-MST is present in the mitochondria and 3-MP has been shown to 
stimulate this process, 3-MST has been hypothesized to be a regulator of mitochondrial 
bioenergetics. It has been shown 3-MST stimulates angiogenesis and would healing in 
mice by intraperitoneal injection of 3-MP [115]. It has been hypothesized that endothelial 
dysfunction due to hyperglycemia occurs partly due to 3-MST pathway impairment. The 
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combination of 3-MP and lipoic acid was able to restore normal angiogenesis and 
mitochondrial function in hyperglycemia. Inhibitors of CAT (aspartate) and CSE (PAG) 
has been found to reduce postischemic cerebral vasodilation, suggesting CAT/3-MST and 
CSE play a role in blood-brain barrier disruption following a stroke [116]. Recently it 
was found 3-MST generates H2S3 and H2S2 polysulfide in addition to H2S in mouse brain 
tissues [109]. Red blood cells contain 3-MST and can produce H2S if provided with 3-
MP and DTT [117]. Red blood cells can also oxidize H2S by hemoglobin to polysulfides 
and thiosulfate.  
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Figure 1.1.2-1 Reverse transsulfuration pathway. Reaction I is the first step of the reverse 
transsulfuration pathway, catalyzed by cystathionine β-synthase (CBS). Reaction II is the 
second step of the reverse transsulfuration pathway, catalyzed by cystathionine γ-lyase 
(CSE). 
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Figure 1.1.2-2 Reactions catalyzed by cystathionine β-synthase (CBS) which produce 
H2S or cysteine persulfide (thiocysteine).  
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Figure 1.1.2-3 Reactions catalyzed by cystathionine γ-lyase (CSE) which produce H2S or 
cysteine persulfide (thiocysteine). 
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Figure 1.1.2-4 Reactions catalyzed by the CAT/3-MST pathway. Reaction I is catalyzed 
by cysteine aminotransferase (CAT). Reaction II is catalyzed by 3-mercaptopyruvate 
sulfurtransferase (3-MST). R represents a sulfur acceptor, which can be cyanide (CN-), 
organic sulfur (eg. glutathione), or an inorganic sulfur (HSO3
-). 
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1.1.3 Chemical Properties of H2S 
When studying H2S in biological systems it’s important to understand the physical 
properties of H2S in order to design accurate experiments and draw appropriate 
conclusions. H2S is a colorless, flammable, toxic gas with a characteristic smell of rotten 
eggs. H2S gas is lipophilic and has a high solubility in organic solvents, allowing it to 
cross cellular membranes, although it is not as highly lipophilic as NO and CO [8, 118]. 
H2S gas is denser than air with a vapor density of 1.19 and in solution it is a weak acid 
that dissociates according to the equilibrium:  
 
pKa1 is around 6.98 at 25 °C, 6.76 at 37 °C, while pKa2 is >17 [119, 120]. As a result H2S 
is approximately 20% H2S and 80% HS
- (hydrosulfide) in solution at physiological 
conditions (37 °C and pH 7.4), and S2- (sulfide) is negligible. Unless otherwise specified 
most researchers refer to all the species in that equilibrium collectively as “hydrogen 
sulfide”. One consequence of H2S equilibrium in solution is H2S solutions release 
gaseous H2S, driving equilibrium to the left, until all the hydrogen sulfide is lost from the 
solution. This has been recognized as a pitfall in H2S research. It has been speculated that 
it contributes to the discrepancy between experimental concentrations required to produce 
biological responses and actual in vivo concentrations. This loss has been shown to be 
significant in open cell culture plates, bubbling tissue baths, and Langendorff apparatus 
[121]. The half-life of H2S in open cell culture plates is only 5 minutes. 
Most commonly used forms of H2S in solution are sodium hydrosulfide hydrate 
(NaSH•xH2O) and sodium sulfide (Na2S•9H2O). Sodium hydrosulfide is only ~60% pure 
and is contaminated with elemental sulfur, yet it is the most commonly used H2S donor. 
Sodium hydrosulfide crystals have a yellow appearance from elemental sulfur. It has 
been hypothesized by Toohey that the biological activity attributed to hydrogen sulfide 
comes from contaminating sulfane sulfur (elemental sulfur), and from oxidation of 
hydrosulfide to sulfane sulfur and polysulfides [122]. The kinetics of H2S release from 
sodium salts may also not be physiologically relevant. Sodium salts are thought to release 
hydrogen sulfide in a large bolus [123]. Additionally sulfide salts create large local 
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concentrations of Na+ [92], the effect of which in relation to H2S research has not been 
studied. An alternative is synthetic H2S donors, such as GYY4137 [124, 125], which are 
thought to release H2S in a slower and more physiologically relevant manner. Many other 
H2S releasing molecules were developed recently due to increasing interest in H2S 
research [126]. Some H2S releasing compounds are also naturally occurring, and it has 
even been hypothesized that the biological activity from garlic (Allium sativum) occurs 
due to H2S [127, 128]. Interest in H2S releasing compounds also stems from development 
of H2S-based therapeutics [126].  
H2S solutions can oxidize to polysulfides, elemental sulfur, and sulfur oxides in 
the presence of oxygen. The chemical species and mechanisms involved are surprisingly 
complex. Oxidation of sulfide has been studied by Chen et al. in 1972 [129]. Sulfide is 
first oxidized by oxygen to elemental sulfur [129, 130]. The oxidation is catalyzed by 
trace metals, as it can be inhibited by the metal chelator DTPA [130]. Sulfur can then 
react with sulfide to produce polysulfides. Polysulfides exist in solution as an 
equilibrium, with different chain lengths present at the same time (Equation 1.1.3-2) 
[122]. 
        
Although Chen et al. initially reported formation of polysulfides with up to 5 sulfurs 
[129], improved detection methods allowed the detection and characterization of 
polysulfides with up to 8 sulfurs [131, 132]. Polysulfide formation is pH dependent, and 
the distribution of polysulfide species is also pH dependent. In 2009 Stasko et al. 
determined the initial oxidation of H2S by oxygen occurs through sulfhydryl radical 
(HS•/S•-) intermediates [133]. Under this reaction mechanism H2S could be directly 
oxidized to polysulfides without forming elemental sulfur intermediates. 
H2S oxidation products also include sulfite (SO3
2-), thiosulfate (S2O3
2-), and 
sulfate (SO4
2-) [129, 130]. The oxidation of H2S combined with the volatility means that 
H2S solutions prepared from sulfide salts need to be made fresh before an experiment. 
Increasing evidence indicates that the H2S-derived biological activity occurs at least 
partly due to polysulfides generated from H2S. Some researchers have used inert gases 
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and metal ion chelators to prevent oxidation of H2S, although such conditions may not be 
physiologically relevant. 
Given that H2S has been shown to act as an anti-oxidant, and sulfur atom in H2S 
is in its most reduced -2 state, H2S can react with a number of physiologically relevant 
redox signaling molecules. H2S can react with superoxide (O2
-), peroxide (H2O2), 
hypochlorous acid (HOCl), peroxynitrite (ONOO-), nitric oxide (NO), lipid peroxide 
(LOOH), various forms of biological iron, and protein disulfides. The subject has been 
reviewed in detail by Li and Landcaster [134]. The mechanisms, kinetics, and biological 
relevance of many of these reactions are still unclear. Of particular interest to researchers 
are reactions between H2S and NO as researchers look for evidence of H2S-NO 
interaction, so called “cross-talk”. Filipovic et al. reported H2S can react with S-
nitrosothiols to form thionitrous acid (HSNO) [135]. HSNO is unstable and can 
decompose into NO+, NO, NO-, and cause protein transnitrosation. It has been 
hypothesized H2S is able to cause transnitrosation of proteins through HSNO in vivo. 
Filipovic et al. also reported that H2S can react with the NO donor sodium nitroprusside 
(SNP) to form nitroxyl (HNO) [136]. It has also been reported that, when catalyzed by 
heme iron, H2S can react with nitrite (NO2
-) to produce NO, as well as HSNO and HNO 
[137]. Cortese-Krott et al. reported that the product of NO and H2S is nitrosopersulfide 
(SSNO−) [138]. Although various S-N hybrid species formed from NO and H2S have 
been reported in vitro at large concentrations of reactants, the physiological relevance of 
such reactions has not yet been demonstrated.  
Although it has previously been proposed that blood concentrations of H2S are in 
the 10-100 µM range [139], it is now clear that H2S is not a circulating gasotransmitter 
[120]. Introduction of H2S in tissues results in rapid H2S catabolism. This is particularly 
highlighted in a study by Whitfield et al. where an extracorporeal pump was used to draw 
blood from the dorsal aorta of rainbow trout, and returned across a polarographic H2S 
sensor into the caudal vein [140]. H2S level was ~0.1 µM at resting state, and when H2S 
was injected into caudal vein cannula, the blood H2S concentration rose to ~1.4 µM 
momentarily and rapidly returned to baseline. The amount of H2S injected was 
theoretically enough to raise the blood H2S concentration to ~30 µM. Half-lives of H2S 
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were also much lower in whole-blood than in buffer. This study demonstrates the highly 
reactive nature of H2S in biological systems. The rapid clearance of H2S from blood is 
likely due to H2S oxidation by hemoglobin [117]. 
1.1.4 Mechanisms of H2S Signaling: S-Sulfuration 
Although H2S can react with other redox signaling molecules and iron, the primary 
mechanism of H2S biological activity is widely-accepted to be protein post-translational 
modification [141]. Similar to S-nitrosation by NO, H2S affects cysteine thiols, where 
H2S can add sulfur to cysteine thiols forming a persulfide thiol (-SSH). Initially this 
process has been termed sulfhydration, which was later criticized for having incorrect 
IUPAC nomenclature, and is now commonly referred to as S-sulfuration or 
persulfuration. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was the first 
protein shown to be S-sulfurated by Mustafa et al. in 2009 [141]. Treatment of purified 
GAPDH with NaSH caused a ~7 fold increase in enzymatic activity with an EC50 of only 
15 µM. S-sulfuration of GAPDH was detected using a modified biotin shift assay, and 
mass spectrometry. Mass spectrometry found the active site Cys 152 (referred to as Cys 
150 in the original publication) to be S-sulfurated. The modified biotin shift assay was 
also used to measure basal S-sulfuration of liver proteins, and it was found that 10% to 
25% of all liver proteins were S-sulfurated. The modified biotin shift assay was 
introduced in the same publication, and it was proposed that the thiol blocking reagent 
methyl methanethiosulfonate (MMTS) does not react with S-sulfurated (-SSH) thiols, and 
only reduced thiols (-SH). After MMTS treatment the protein was treated with biotin-
HPDP to label S-sulfurated thiols. The nature of the selectivity of MMTS or the product 
of reaction between biotin-HPDP and persulfide was not explored in the 2009 
publication.  
 Mass spectrometry is generally used to detect S-sulfuration in vitro after treating a 
purified enzyme with H2S, while variations of the biotin shift protocol have been used 
combined with western blotting to detect S-sulfuration in cells. This can be problematic if 
the reagents used for biotin shift labelling are not specific for S-sulfuration. The MMTS 
selectivity of the modified biotin shift assay was tested by Pan and Carroll in 2013 [142]. 
MMTS, as well as other commonly thiol-reactive reagents, were reacted with persulfides 
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(S-sulfurated thiols) and analyzed by LC-MS. It was found that MMTS is not selective to 
persulfides, and persulfide thiols act as a nucleophile to produce a mixed disulfide 
product (-SSCH3). The same reaction occurs between persulfides and other commonly 
used thiol reactive reagents like iodoacetamide and N-ethylmaleimide. Persulfides may 
also react with disulfides like DTNB to form a trisulfide linkage. Two possible 
mechanisms were proposed for the observed signal in the modified biotin shift assay; 
incomplete labelling of thiols with MMTS will produce a positive signal after labelling 
with biotin-HPDP; or trace amount of thiols can reduce the dithiomethane linkage from 
MMTS labelling, and biotin-HPDP can label the resulting free thiol. It is possible that 
numerous publications on the sulfuration of proteins are actually reporting cysteine 
reduction and not S-sulfuration of cysteines. The increase in modified biotin shift assay 
signal with increasing H2S concentration is likely due the second mechanism. Challenges 
in detecting S-sulfuration using mass spectrometry include the mass increase resulting 
from S-sulfuration (31.9721 Da) is very close to that to sulfonic acid (-SO2H) (31.9898 
Da). It has also been suggested that unmodified protein persulfides may not be stable 
under mass spectrometry conditions [143]. 
In the majority of S-sulfuration studies so far, proteins were shown to be S-
sulfurated using the modified biotin shift assay. For example IKCa ion channels and the 
Kir 6.1 subunit of ATP channels have been shown to be S-sulfurated using the modified 
biotin switch assay [29, 144]. H2S has been postulated to act as an endothelium 
hyperpolarizing factor and fulfill this function through S-sulfuration. Other enzymes that 
have been reported to be S-sulfurated include PTP1B, a protein tyrosine phosphatase, 
where S-sulfuration of its active site cysteine inactivated the enzyme [145]. S-sulfuration 
was detected by mass spectrometry, and a biotinylated iodoacetic acid probe. However, it 
is unclear how an iodoacetic acid based probe can be selective for S-sulfurated thiols, and 
not react with free thiols. The p65 subunit of nuclear factor kappa B (NF-κB) has been 
shown to the S-sulfurated using the modified biotin shift assay, a maleimide assay for S-
sulfuration and S-nitrosation, and mass spectrometry to pinpoint the modification [146]. 
The maleimide assay involves reaction of protein thiols with two versions of fluorophore-
conjugate maleimide. First free thiols and S-sulfurated thiols are reacted with red 
maleimide (Alexa Fluor® 680 C2 maleimide), ascorbate is added to denitrosate S-
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nitrosothiols, and S-nitrosothiols are labelled with green maleimide (Alexa Fluor® 488 
C5 maleimide or IRDye 800CW). Finally DTT is added to cleave the protein-maleimide 
disulfides formed from labeling persulfides with red maleimide, and loss of red 
fluorescence corresponds to S-sulfuration. H2S has been hypothesized to be an in vivo 
modulator of NF-κB activity. S-sulfuration of NF-κB p65 was also studied using the 
modified biotin shift assay [147].  
H2S has been linked to Parkinson’s disease since human brain samples from 
Parkinson’s disease patients showed reduced S-sulfuration of parkin [148]. In this study 
endogenous S-sulfuration in cells and tissues was detected using a maleimide assay for S-
sulfuration and S-nitrosation. The modified biotin switch assay was used to detect S-
sulfuration in Hek293 cells transfected with parkin. Sites of S-sulfuration were 
determined using purified protein and mass spectrometry. Liu et al. studied the effect of 
H2S on bone marrow mesenchymal stem cells (BMMSCs) [149]. It was determined H2S 
is required for BBMSC self-renewal and differentiation. The effect was attributed to Ca2+ 
channel S-sulfuration. S-sulfuration of ion channels was determined using multiple 
methods including Ellman’s reagent (DTNB); although not specific to S-sulfuration, live 
cells were added to a solution of DTNB to measure S-sulfuration on cell surfaces. TRPV6 
calcium channel was immunoprecipitated and analyzed for S-sulfuration by a maleimide 
assay where only one fluorophore-conjugated maleimide was used (Alexa Fluor® 488 C5 
maleimide) to test for S-sulfuration but not S-nitrosation. After treatment with maleimide, 
the protein was treated with DTT to reverse protein-maleimide disulfides formed from 
reaction with persulfides. The loss of fluorescence after DTT treatment has been 
correlated to S-sulfuration. Mass spectrometry was used to find S-sulfurated cysteine 
residues on TRPV6 channel from cells treated with NaSH. S-sulfuration of GAPDH was 
also studied using this type of assay, as well as modified biotin shift, by Mir et al. in 2014 
[150]. Other proteins shown to be S-sulfurated using the modified biotin shift assay 
include Keap [151, 152], MEK1 [153], PLN [154], androgen receptor (AR) [155], eNOS 
[156], Kv4.3 [157], PTEN [158], and pyruvate carboxylase [159].  
Zhang et al. developed a tag-switch technique for detecting S-sulfuration [160]. 
The technique involves reacting free thiols (-SH) and persulfides (-SSH) with a thiol 
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blocking reagent. After the reaction thioether linkages are formed from free thiols, and 
disulfides are formed from persulfides.  After addition of a nucleophile, the nucleophile 
will react with disulfides, and not thioethers, selectively labeling the persulfides. One 
important consideration for the design of the assay is the first blocking reagent must give 
a chemical linkage with properties different from native protein disulfides. Commonly-
used thiol blocking reagents like iodoacetamide and maleimides produce linkages which 
are chemically similar to native protein disulfides. This would result in native protein 
disulfides being labelled with the second reagent. To generate a linkage different from 
native protein disulfides, the authors used methylsulfonyl benzothiazole (MSBT) to label 
free thiols and persulfides. Derivatizing with MSBT generates an activated disulfide 
linkage which has high reactivity to nucleophiles. The nucleophile chosen was methyl 
cyanoacetate (MCA), which was biotin-linked. Using the technique the investigators 
detected S-sulfuration of GAPDH after NaSH treatment. GAPDH was S-sulfurated at 
basal conditions as well, although the signal was very weak. The technique was also used 
to visualize S-sulfuration in cells by fluorescent microscopy when exposed to fluorescein-
labeled streptavidin. 
H2S cannot react with free cysteine thiols directly and needs additional oxidants to 
S-sulfurate proteins (Equations 1.1.4-1 & 1.1.4-2). Thiols in H2S and free cysteines (-SH) 
are both in their most reduced oxidation states (-2) [161]. It may be possible for H2S, in 
the form of sulfide (HS-), to react with disulfides resulting in an S-sulfurated thiol and a 
free thiol (Equation 1.1.4-3).  
 
 
 
Francoleon et al. investigated the reaction of disulfides with H2S by reacting oxidized 
glutathione (GSSG) and oxidized papain with H2S [162]. Papain is a cysteine protease 
and a reduced cysteine is required for catalytic activity. It was found H2S can reduce 
GSSG to form a glutathione persulfide (GSSH) and reduced glutathione (GSH). When 
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treated with low concentrations of H2S, the enzymatic activity of papain decreased, while 
S-sulfuration increased. At higher concentrations of H2S the S-sulfuration of papain 
decreased, while the activity increased. It was theorized that at low H2S concentrations; 
H2S acts as an S-sulfurating agent, while at higher H2S concentrations; excess H2S can 
act as a reducing agent for protein persulfides and regenerate the free thiol. It has been 
reported that the H2S can activate vascular endothelial growth factor receptor 2 
(VEGFR2) by cleaving a disulfide bond between Cys 1045 and Cys 1024 [163]. Greiner 
et al. reported that H2S can cause protein oxidation through polysulfides [143]. This is an 
interesting finding since the work by Francoleon et al. suggests H2S acts as a reducing 
agent. It was found different H2S donors can reduce the enzymatic activity of PTEN by 
thiol oxidation through polysulfides. H2S donor GYY4137 was also able to produce 
polysulfides, and the effect is not only attributed to sulfide salts. The mechanism of 
oxidation was determined to be S-sulfuration of active site Cys 124, followed by 
formation of an internal disulfide between Cys 124 and nearby Cys 71.  
Other mechanisms of S-sulfuration have been postulated to be reaction of H2S 
with protein sulfenic acids (-SOH), S-nitrosothiols (-SNO), trans-sulfuration between 
proteins, and reaction of reduced protein thiols with polysulfides generated from H2S 
[94]. Although H2S cannot react with reduced cysteines directly, polysulfides generated 
from H2S oxidation may. Equation 1.1.4-4 shows the proposed reaction of a reduced 
protein thiol with a polysulfide resulting in S-sulfuration. 
 
In addition to S-sulfurating protein thiols H2S has been shown to react with and sulfurate 
8-nitro cGMP (8-nitroguanosine 3′,5′-cyclic monophosphate) to form a novel secondary 
messenger 8-SH cGMP [164]. The reaction of H2S and 8-nitro cGMP was later shown to 
be mediated by polysulfides [165]. Increasing evidence shows that polysulfides are 
important H2S derived molecules, and protein S-sulfuration may occur through 
polysulfides. Although protein polysulfides (e.g. -SSSH) have been predicted, they have 
not been reported in the literature, and S-sulfuration appears to involve the addition of 
only one sulfur to cysteines (-SSH). 
 23 
 
1.1.5 Tissue Levels of H2S 
A very wide range of H2S concentrations have been reported in blood and tissues ranging 
from undetectable to as high as 600 µM [166]. This issue has been reviewed several times 
and stems from the use of unreliable detection methods for H2S in biological systems 
(vide infra) [92, 120, 130, 166]. Sometimes working experimental concentrations, i.e. the 
concentration of exogenous H2S required to produce a biological effect, or H2S 
production stimulated by the addition of cysteine, may be reported as a tissue 
concentration. Most commonly reported blood H2S concentrations are in the 10-100 µM 
range [166]. The human nose is very sensitive to H2S; Furne et al. reported a 1 µM 
solution in pH 7.4 buffer produces a “detectable, but weak” odour, while a 5 µM solution 
is “unpleasant” [167]. This observation and other experiments indicate many reported 
H2S tissue concentrations are not accurate. Furthermore, calculations by researchers 
suggest that the human body does not contain enough cysteine and sulfur to maintain H2S 
production at the commonly reported micromolar levels [166, 167]. Micromolar H2S 
concentrations are also high enough to be toxic; in cell homogenates NaSH inhibited 
cytochrome c oxidase with an IC50 of only 0.32 µM [168]. 
 When measured using detection methods that are considered more reliable, 
endogenous H2S concentrations are in the submicromolar range. Furne et al. reported 
brain and liver H2S concentrations following 30 s homogenation as 14 ± 3 nM and 17 ± 3 
nM using gas chromatography [167]. Whitfield et al. was unable to detect H2S in trout 
blood using real time measurement with a polarographic H2S sensor [140]. Wintner et al. 
found rat blood H2S levels were in the 0.4–0.9 µM range using an HPLC method [169]. 
Experiments by Whitfield et al. also showed H2S is rapidly catabolized in the blood (vide 
supra) [140]. Experiments where H2S was intravenously administered to rats while 
exhaled H2S was simultaneously measured showed H2S was rapidly cleared when 
intravenous administration was stopped [170]. It is now clear H2S is not a circulating 
gasotransmitter and reacts rapidly in the presence of tissues [120]. Due to the reactivity of 
H2S with a large number of different compounds, a clear and convenient biomarker of 
H2S catabolism or turn-over does not exist [92]. While H2S tissue concentrations are low 
and production by CBS and CSE is relatively low, usually relatively high H2S 
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concentrations required to produce biological effects. For instance high micromolar 
concentrations are required to produce vasorelaxant effects of H2S [92]. Production by 
CBS and CSE may be insufficient to explain the biological activities attributed to 
endogenous H2S [171].  
In addition to free H2S, two other sulfide sources are present in biological 
systems, acid-labile sulfide, and sulfane sulfur, also known as reductant labile sulfur or 
bound sulfur [172, 173]. Acid-labile sulfide is sulfide contained in iron-sulfur clusters 
contained in non-heme iron-containing proteins, which upon treatment with acid release 
sulfide. Sulfane sulfur refers to a divalent sulfur atom which is bonded to another sulfur 
atom. Sulfane sulfur species include persulfides (R-S-S-), polysulfides (RSnSR), 
thiosulfate (S2O3
2-), thiosulfonates (R-S2O2
-), polythionates (-SO3-Sn-SO3
-), and elemental 
sufur (S8). Treatment with a reducing agent such as DTT may release sulfide from 
sulfane sulfur species [173]. Depending on the sample handling and analytical method, 
sulfide may be released from these two sources during experiments leading to an over-
estimation of free H2S [120]. 
1.1.6 H2S Detection Methods 
The most commonly used and the oldest method of H2S detection is the methylene blue 
method [1, 174]. The methylene blue method is a spectrophotometric method based on 
the reaction of iron (III) chloride (FeCl3) and N,N-dimethyl-p-phenylenediamine (NDPA) 
in the presence of HCl. The method involves trapping of H2S from biological samples 
through the use of zinc acetate, and variations of the H2S extraction and trapping 
procedure has led to two versions of the method, the direct, and indirect [166]. Zinc 
reacts with H2S to form zinc sulfide (ZnS). In the direct method zinc acetate is added 
directly to the H2S-containing sample, proteins are removed from the sample by 
precipitation with trichloroacetic acid (TCA), and the zinc sulfide is reacted with NDPA 
in the presence of FeCl3 and HCl. In the indirect method a piece of filter paper is soaked 
in zinc acetate and placed in a sealed flask with the sample. Due to its volatility, H2S is 
slowly driven from the sample into the gas phase and reacts with the zinc acetate on filter 
paper. The filter paper is then removed and reacted with NDPA in the presence of FeCl3 
and HCl. The final reaction with NDPA is usually incubated for 30 minutes to allow the 
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formation of methylene blue. The solution is measured spectrophotometrically at 670 nm, 
and is stable for hours. 
The methylene blue method has the advantages of being inexpensive, easy to use, 
and requires no specialized equipment. The major flaw with the methylene blue method 
is the use of acidic conditions in the direct methylene blue method may cause protein 
desulfuration and release acid labile sulfur from biomolecules [120, 166, 172, 175, 176]. 
Effectively, the methylene blue method is measuring bound sulfur in addition to free H2S 
and vastly overestimating the H2S concentration. When using the indirect methylene blue 
method acids such as TCA may be added to tissues [177], which results in the same 
issues as with the direct method. The detection limit for the methylene blue method is 2 
µM [176], making it unsuitable for detection of submicromolar concentrations of H2S. 
Methylene blue has also been reported to form dimers and trimers, and as a result may 
not follow Beer’s law [178].  
Another commonly used H2S detection method is the sulfur specific ion selective 
electrode (ISE) [140, 179]. This method is actually selective towards S2- and requires 
highly alkaline conditions to convert H2S to S2
-. Similarly to the acid conditions in the 
methylene blue method, the alkaline conditions employed using the ISE cause drastic 
alterations in biological samples [120, 166]. The standard buffers used with the ISE are 
known to cause cysteine desulfuration, for example the alkaline conditions can release 
sulfide from bovine serum albumin [140]. Like the methylene blue method, the ISE is not 
specific to free H2S, and use of this method for measuring free H2S leads to 
overestimation. Like the methylene blue method, it is also unsuitable for real-time 
measurements.  
H2S can be detected by high-performance liquid chromatography (HPLC) or gas 
chromatography (GC). Detection with HPLC involves derivatization with the thiol-
reactive probe monobromobimane [169, 176, 180]. Two equivalents of 
monobromobimane react with sulfide to form a fluorescent sulfide dibimane molecule 
which can be separated and detected by HPLC with a fluorescence detector. This method 
is also an endpoint method. The optimum conditions for the derivatization reaction were 
found to be pH 9.5, 1% O2 atmosphere, and the presence of the metal chelator DTPA 
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[176]. The limit of detection was 5 nM. The method has also been adapted to measure 
acid labile sulfide and reductant labile sulfide in addition to free H2S [173]. Although the 
monobromobimane level is vastly more accurate and sensitive than the methylene blue 
method, Wintner et al. reported discrepancies between monobromobimane detection and 
the polarographic H2S sensor when measuring Na2S spiked human blood [169]. While 
the polarographic H2S sensor showed rapid tissue catabolism of H2S, monobromobimane 
did not, and showed a gradual decrease in H2S level over time. The authors suggest 
monobromobimane may be reacting with the sulfide-containing products of H2S 
catabolism in tissues. H2S can also be detected by headspace analysis using GC when 
coupled to a sulfur chemiluminescence detector [167, 175, 181, 182]. Since gaseous 
headspace is being analyzed this method is specific to free H2S gas. Like HPLC, GC is an 
end-point measurement. 
The polarographic (amperometric) H2S sensor is a modification of the Clark-type 
oxygen microsensor [140, 183, 184]. This sensor is the only commonly used real-time 
method of H2S measurement. The specificity to free H2S is due to the use of a gas-
permeable polymer membrane that separates the anode, cathode, and the electrolyte 
solution from the sample being measured [184]. The electrolyte solution contains 
ferricyanide ([Fe(CN)6]
3-), which is reduced at the anode to ferrocyanide ([Fe(CN)6]
4-) 
and re-oxidized at the cathode, which generates a background current. After it diffuses 
through the gas-permeable membrane, H2S reduces ferricyanide to ferrocyanide, 
generating a current which is subtracted from the background current. Detection limits of 
10 nM [184] and 14 nM [140] have been reported. Since the sensor consumes H2S it 
might not be appropriate for measurement of low volume samples [166]. The use of a gas 
permeable membrane has also been used to detect free H2S using the thiol-reactive probe 
5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) by Faccenda et al. [185]. 
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1.2 Nitric Oxide 
 1.2.1 Introduction and Biological Functions of NO 
Nitric oxide (NO) is an important gasotransmitter synthesized in mammalian tissues. A 
number of studies by multiple research groups in the late 1970’s and 1980’s led to the 
identification of NO as the endothelium derived relaxing factor (EDRF), and later the 
arginine-NO pathway which synthesizes NO. In 1977 Murad et al. discovered NO could 
activate guanylate cyclase and generate cyclic GMP [186]. However, at the time NO was 
not known to be produced in the body, and was most well known as a toxic pollutant. In 
1980 Furchgott and Zawadzki observed endothelium-dependent vasorelaxation, where 
acetylcholine relaxed isolated blood vessels only when the endothelium was intact [187]. 
It was later discovered acetylcholine stimulated the release of an unknown compound 
dubbed the endothelium derived relaxing factor (EDRF), which can be inhibited by 
methylene blue and hemoglobin, suggesting EDRF was a free radical [188]. In 1986 
Gryglewski et al. discovered EDRF can be inhibited by superoxide anion (O2
-) and 
protected by superoxide dismutase (SOD) [189]. In 1987, based on the accumulating 
evidence, Furchgott, Ignarro, and Moncada each identified EDRF as nitric oxide [2, 190, 
191]. In 1988 Moncada discovered NO is synthesized from L-arginine [192, 193]. Thus 
the field of NO biochemistry was born. The 1998 Nobel Prize in medicine was awarded 
to Furchgott, Ignarro, and Murad for their discoveries concerning NO. Moncada was 
somewhat controversially excluded from the prize due to the policy of awarding the prize 
to only three individuals.  
 While a vast number of physiological processes are affected by NO the major role 
of NO is control of vascular tone [194]. NO is synthesized in vascular endothelium, after 
which it diffuses to the surrounding vascular smooth muscle, and activates soluble 
guanylate cyclase causing an increase in intracellular cGMP. The increase in cGMP 
triggers a signal cascade, which causes a decrease in intracellular Ca2+ and results in 
vasorelaxation [195]. NO is a major determinant of basal vascular tone, and 
pharmacological inhibition of NOS raises systolic blood pressure [196]. NO production 
in endothelial cells is controlled by a number of different stimuli [194], the major being 
endothelial shear stress [197]. Control of vascular tone and blood pressure by NO is 
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ubiquitous to all mammals, and some, but not all, non-mammalian vertebrates [198]. 
Penile erection is controlled by NO, and drugs used to treat erectile dysfunction such as 
sildenafil (Viagra®) alter NO homeostasis [199-201]. NO synthesized in endothelial cells 
also prevents platelet aggregation [202]; this protects blood vessels against thrombosis, 
and atherosclerosis [203]. NO mediates angiogenesis and wound healing [204-206]. NO 
produced by iNOS in macrophages is responsible for antimicrobial activity of 
macrophages [207]. In the nervous system NO controls vascular tone, and acts as a 
neuromodulator; affecting long-term potentiation, learning, and memory [208].  
1.2.2 NO-Producing Enzymes 
Nitric oxide is synthesized by three isoforms of nitric oxide synthases (NOS), named 
either after their localization (endothelial NOS, neuronal NOS), or by their basal level of 
NO production (inducible NOS). All nitric oxide synthases are homodimers, and require 
flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), and 
tetrahydrobiopterin (BH4) as co-factors [201]. Two isoforms of NOS; neuronal NOS 
(nNOS, NOS1), and endothelial NOS (eNOS, NOS3) are regulated by intracellular Ca2+ 
through calmodulin [201]. Inducible NOS (iNOS, NOS2) also binds calmodulin, however 
the binding is not affected by intracellular Ca2+ concentration, and instead the enzyme is 
constitutively active. Nitric oxide synthases convert L-arginine and O2 to L-citrulline and 
NO, using nicotinamide adenine dinucleotide phosphate (NADPH) as a co-substrate. For 
every mol NO formed NOS requires 2 mol O2 and 1.5 mol NADPH [209].  
nNOS is constitutively expressed in the brain, although it is not exclusively 
localized to the brain [210]. nNOS maintains synaptic plasticity and blood pressure in the 
nervous system [201]. nNOS is also present in the peripheral nervous system, and has 
been detected in epithelial cells of lung, uterus, stomach, in kidney macula densa cells, 
pancreatic islet cells, and human skeletal muscle cells [209, 210]. Although eNOS is 
largely responsible for vasodilation outside of the nervous system, accumulating evidence 
shows nNOS also contributes [211]. eNOS is expressed mostly in endothelial cells and is 
responsible for endothelium-dependent vasorelaxation and vasoprotective effects of NO 
[201]. iNOS is expressed in macrophages and is responsible for the cytotoxic effects of 
NO. 
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1.2.3 Mechanisms of NO Signaling: cGMP and S-Nitrosation 
The major mechanisms of NO action are through the secondary messenger cGMP and 
protein post-translational modification (S-nitrosation). The vasodilation effects of NO are 
mediated through the cGMP dependent pathway. NO activates soluble guanylate cyclase 
(sGC) by binding to sGC heme iron in an ATP and GTP dependent manner [212]. 
Activation of sGC causes an increased production of the secondary messenger cGMP, 
which activates cyclic GMP-dependent protein kinase (also known as Protein Kinase G, 
PKG, cGK) [213]. The number of targets for PKG is vast [214]. In the case of vascular 
smooth muscle relaxation, the activation of PKGI causes a decrease in intracellular Ca2+, 
which decreases the activity of myosin light kinase (MLCK), decreases myosin light 
chain phosphorylation and leads to vasorelaxation. Decrease in intracellular Ca2+ is 
caused by multiple molecular targets of PKGI, and not a single factor. cGMP-dependent 
NO signaling has been described as the “classic” NO signaling pathway [195].  
NO may modify cysteine residues by S-nitrosation, which is the attachment of 
NO-derived nitrosonium (NO+) to cysteine, to form S-nitrosocysteine (R-SNO). The 
modification is also commonly called S-nitrosylation. S-nitrosation of a protein is 
dependent on the chemical microenvironment; the presence of S-nitrosating species, 
cellular compartmentalization, and the degree of cysteine reactivity [195]. S-nitrosation is 
particularly gaining interest in pathophysiological states where hyper- or hypo- S-
nitrosation of proteins contribute to pathophysiology of various diseases [215, 216]. 
Rather than general hyper-S-nitrosation from increased nitosative and oxidative stress, 
changes in S-nitrosation status of specific proteins are changed in disease states. Changes 
in protein S-nitrosation has been implicated in the pathology of cardiovascular disease, 
sickle cell anemia, cancer, pulmonary arterial hypertension, diabetes, malignant 
hyperthermia, and neurodegenerative diseases like Parkinson’s disease and Alzheimer’s 
disease [215, 216]. 
NO cannot react directly with cysteine thiols to form S-nitrosothiols. For S-
nitrosation to occur, NO first needs to be oxidized. The mechanisms of S-nitrosothiol 
formation in vivo have been reviewed by Broniowska and Hogg [217]. Two possible S-
nitrosating agents are dinitrogen trioxide (N2O3) and nitrogen dioxide (NO2) which can 
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be formed by the oxidation of NO by O2. N2O3 may react with thiols directly to form an 
S-nitrosothiol (Equation 1.2.3-1). 
 
Another pathway for S-nitrosothiol formation is NO2 reacting with thiols to form thiyl 
radicals (RS•). Thiyl radicals may then react with NO directly with to form S-
nitrosothiols (Equations 1.2.3-2 & 1.2.3-3). 
 
 
Although N2O3 and NO2 provide a pathway for S-nitrosothiol formation, some questions 
remain about the kinetics of the initial oxidation of NO to NO2 and N2O3, which are slow 
under physiological NO and O2 concentrations [217]. S-nitrosation of proteins may also 
occur through transnitrosation reactions with small molecular weight S-nitrosothiols like 
S-nitrosoglutathione (GSNO) (Equation 1.2.3-4). 
 
Interestingly cytochrome c can promote the formation of GSNO through its heme iron 
[218, 219]. The increased GSNO formation in-turn promotes protein S-nitrosation. 
Another possible pathway for S-nitrosation is through dinitrosyl iron complexes (DNIC) 
which can S-nitrosate proteins by transnitrosation [220-222]. DNIC are complexes with 
NO, iron, and either small molecular weight thiols or protein thiols. The relative 
contribution of various S-nitrosation mechanisms in vivo is still unknown. 
 1.2.4 Role of NO in Wound Healing 
Wound healing is an incredibly complex and coordinated process which can be divided 
into three overlapping phases; inflammation, tissue formation, and tissue remodeling 
[223]. This process is controlled by numerous cytokines that act on many different cell 
types. NO has been shown to be important factor in wound healing, and affect the activity 
of these cytokines [206]. Even before the discovery of NO as a gasotransmitter it has 
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been shown arginine-deficient animals showed impaired wound healing [224]. Increased 
arginine metabolism and conversion to citrulline has been observed in wounds [225]. 
Urinary NO2
-, a biomarker for NO, increases dramatically after injury, and remains 
elevated during healing [226]. Both eNOS [227], and iNOS [228] knockout mice have 
exhibited impaired wound healing. Although iNOS is highly upregulated during 
inflammation, NO plays a role in all stages of wound healing [229]. The production and 
action of many growth factors necessary for wound healing is NO-dependent. For 
example the production of vascular endothelial growth factor (VEGF) is NO-dependent 
[230], as well as the downstream effects of VEGF [231]. VEGF is one of many cytokines 
responsible for angiogenesis during wound healing [223]. In addition to cytokines, 
numerous enzymes and transcription factors involved in wound healing are affected by 
NO. Numerous animal studies have been conducted on the efficacy of NO-releasing 
materials on cutaneous wound healing [232-241]. The development of NO-releasing 
wound dressings is however hampered by the inconvenient chemistry of commonly-used 
NO-releasing groups. The most commonly used NO-releasing groups, diazeniumdiolates 
(NONOates) and S-nitrosothiols, are simple to prepare, however exhibit short or very 
short half-lives [242]. S-nitrosothiols are also temperature sensitive. The second 
challenge is, NO-releasing materials cannot merely release NO to be beneficial, and must 
have other properties which make it appropriate to use as a wound dressing [233]. 
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CHAPTER 2 
 
MICROPLATE-BASED COLOURIMETRIC DETECTION OF FREE H2S 
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2.1 Introduction 
Driven by the need for sensitive and specific detection methods in H2S research we 
sought to develop a new method for H2S detection. This method was inspired by lead 
acetate test strips for H2S, and the use of zinc acetate in the methylene blue method. In 
the lead acetate test, lead reacts with H2S to form a black PbS precipitate, which serves as 
a quick chemical test for H2S [243]. Similarly, in the methylene blue method H2S reacts 
with zinc acetate to form ZnS, which is further reacted to form methylene blue [174]. The 
chemical basis for our assay is the reaction of Ag+ with H2S to form Ag2S. This reaction 
has been used to synthesize Ag2S nanoparticles, which have a high absorbance in the low 
wavelength visible and UV range [244]. The assay has been adapted to the 96-well plate 
microplate format, and takes advantage of the volatility of H2S. The underside of a 
microplate cover, the circular area directly over the wells, was coated with a solution 
containing Nafion, glycerol, and AgNO3. Nafion is a tetrafluoroethylene based polymer 
with regularly spaced perfluorovinyl side chains terminated with a sulfonate group. The 
combination of a hydrophobic backbone and hydrophilic side chains results in a polymer 
which forms a reverse micelle nanostructure [245]. The reverse micelle pores are 4-5 nm 
in diameter and has been used for templated nanoparticle synthesis [246, 247]. Solutions 
of sulfide spontaneously release gaseous H2S according to Equation 2.1-1 [121]. When 
open to the atmosphere the equilibrium is driven to the left until virtually all the sulfide is 
lost as H2S gas. The released H2S will interact with the bottom of the microplate cover 
and react with Ag+ to produce Ag2S nanoparticles (Equation 2.1-2). The formation of 
Ag2S can be monitored in real time using spectroscopy and is proportional to the H2S 
concentration of the solution. 
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2.2 Materials 
2.2.1 Reagents 
Costar 96-well plates (3370) were purchased from Corning Life Sciences. Nafion 
LIQUIONTM (LQ-1115) dispersion was purchased from Ion Power Inc. 
(www.nafionstore.com). Glycerol (G3700) was purchased from ACP Chemicals. AgNO3 
was purchased from Fisher Scientific. Na2S•9H2O (02152580) was purchased from MP 
Biomedicals. 
2.2.2 CSE Purification 
Recombinant CSE was purified according to the detailed protocol described by Faccenda 
et al. [185]. 
2.2.3 Animals and Tissue Collection 
Mouse livers were provided by Dr. Lisa Porter (University of Windsor). All experimental 
techniques complied with the guidelines set forth by the University of Windsor animal 
care committee. BALB-c mice were purchased from The Jackson Laboratory (Bar 
Harbor, USA). The mice were housed at the University of Windsor animal care facility. 
Mice were euthanized by CO2 inhalation. The liver was removed and placed on ice.  
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2.3 Methods 
2.3.1 Nafion-Coated Microplate Cover Fabrication 
Nafion dispersion (LQ-1115) was mixed with glycerol in a 4:1 ratio. AgNO3 was added 
from a 100 mM solution in Milli-Q H2O to a final concentration of 3 mM. The solution 
was mixed well by vortexing. 15 µL of the solution was carefully pipetted (in order not to 
introduce bubbles) onto each well on the underside of a microplate cover. The cover was 
dried at room temperature for at least 1 hour before use.  
2.3.2 Microplate Measurements 
For all H2S measurements using the assay system, the absorbance of the entire microplate 
along with the Nafion-coated microplate cover was measured. All solutions were spaced-
out in the microplate wells. In a microplate row, a well adjacent to a sample was left 
empty, and the next sample was loaded into the well following the empty well. An entire 
row below or above solution-containing samples was also left empty. As a result a 
maximum of 24 samples were measured per 96-well microplate. All measurements were 
done using a Spectramax 384 plate reader at 310 nm. 
2.3.3 Standard Curve and Specificity Test 
Na2S standard solutions were diluted in 100 mM phosphate buffer (pH 7.0). 300 µL of 
each dilution was pipetted into the 96-well plate and the plate was covered immediately 
with the fabricated Nafion-coated cover. H2S was allowed to form from Na2S for 1 h. The 
absorbance of the microplate and cover was then measured to generate a standard curve. 
To test specificity of the assay system, cysteine (Sigma), reduced glutathione (Sigma), 
and DTT (MP Biomedicals) were compared to Na2S using the same methodology. 
 2.3.4 LoD Determination 
The limit of detection (LoD) for the assay was determined according to the EP17 
guideline published by the National Committee for Clinical Laboratory Standards 
(NCCLS) [248, 249]. The LoD (limit of the detection) is defined as the lowest analyte 
concentration that can be reliably differentiated from the LoB (limit of blank). The LoB 
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is the highest apparent concentration that can be produced by a blank sample. 72 
replicates of a blank sample (300 µL 100 mM pH 7.0 phosphate buffer), and 72 replicates 
of a low concentration sample (300 uL 10 µM Na2S in 100 mM pH 7.0 phosphate buffer) 
were used for the calculations. 
2.3.5 CSE Assay 
CSE was diluted to a final concentration of 0.29 µg/µL in pH 8.0 100 mM phosphate 
buffer with 2 mM EDTA. PLP was added to the enzyme to a final concentration of 25 
µM. 295 µL of cysteine dilutions in the same buffer (without PLP) were added to the 96-
well plate, and the plate including the cover was pre-incubated at 37°C for 15 minutes in 
the plate reader. 5 µL of the enzyme mixture was added to each cysteine dilution and the 
assay was run for 40 minutes at 37°C. Absorbance at 310 nm was measured every 20 s. 
Data was fit into a Michaelis-Menten equation using the Solver function in Microsoft 
Excel to calculate kinetic parameters. For determination of the kinetic parameters of CSE 
the tail of each real time curve (1900-2400 s) was chosen to calculate the enzymatic rate. 
2.3.6 Mouse Liver Homogenate H2S Production 
An endpoint assay was conducted since homogenate solutions absorb UV light. To 
accomplish this, two different microplates were used, and the Nafion-coated cover was 
switched between them during the experiment. One microplate was used for absorbance 
readings, and one for incubating the homogenate. Prior to the trial, the Nafion-coated 
microplate cover was read on the first microplate to establish baseline absorbance. Mouse 
liver was homogenized in PBS using a glass dounce homogenizer. Commercial protease 
inhibitor cocktail (Sigma P8340) was added in a 1:100 ratio to the homogenate. 200 uL of 
the homogenate was pipetted into the second microplate. L-cysteine was added to the 
homogenate to a concentration of 5 mM. The Nafion-coated cover was placed 
immediately on the second microplate with the homogenate and cysteine mixture. The 
microplate was incubated at 37 °C for 40 min. Afterwards, the Nafion-coated cover was 
transferred from the second microplate (with homogenate), to the first one (blank) to 
measure the change in absorbance. 
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2.4 Results 
 
 
Figure 2.4-1 Schematic of the H2S assay. H2S is volatilized in the microplate well, and 
reacts with the silver ions on the underside of the Nafion/Ag-coated microplate cover to 
produce silver sulfide, which is quantified spectrophotometrically. Adapted from [250] 
with permission. 
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Figure 2.4-2 A photograph of the Nafion/Ag-coated 96-well plate cover after exposure to 
100 mM pH 7.0 phosphate buffer with various concentrations of Na2S, dithiothreitol 
(DTT), reduced glutathione (GSH), and L-cysteine (Cys). Adapted from [250] with 
permission. 
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Figure 2.4-3 Corrected absorbance of the Nafion/Ag-coated 96-well plate cover after 
exposure to 100 mM pH 7.0 phosphate buffer with various concentrations of Na2S, 
dithiothreitol (DTT), reduced glutathione (GSH), and L-cysteine (Cys). Adapted from 
[250] with permission.  
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Figure 2.4-4 UV−vis spectrum of a blank microplate and cover (black, dashed), the 
microplate with cover coated with Nafion containing Ag+ ions (blue, solid), and the same 
microplate and cover after exposure to 300 µL of 100 µM Na2S solution in pH 7.0 100 
mM phosphate buffer for 1 h (red, solid). The resulting UV−vis spectrum (red, solid) is 
characteristic of Ag2S nanoparticles. Adapted from [250] with permission. 
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Figure 2.4-5 Standard curve for the colourimetric microplate H2S assay. Na2S was used 
as a H2S donor in 300 uL pH 7.0 100 mM phosphate buffer. Absorbance was measured 
after 1 h. Error bars represent the standard deviation (n=3). Adapted from [250] with 
permission. 
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Figure 2.4-6 H2S generation by CSE, with various concentrations of L-cysteine, 
measured by the colourimetric microplate assay. Adapted from [250] with permission. 
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Figure 2.4-7 Single Michaelis-Menten plot of CSE activity using L-cysteine as a 
substrate. Three plots were generated to calculate the KM and Vmax of the enzyme. 
Adapted from [250] with permission. 
 
Table 2.4-1 Kinetic parameters of recombinant CSE enzyme, and mouse liver 
homogenate H2S production determined by the colourimetric microplate assay. The 
values are averages of three trials (n=3), with standard deviations. L-cysteine was used as 
a substrate for CSE. Homogenates were aerobically incubated with 5 mM L-cysteine. 
Adapted from [250] with permission. 
CSE KM 11.13 ± 0.57 mM 
CSE Vmax 0.45 ± 0.01 nmol min
-1 
Mouse liver H2S 
production 
4.89 ± 0.19 nmol min-1 mL-1 homogenate 
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2.5 Discussion 
 2.5.1 Assay Design and Microplate Cover Preparation 
A Nafion dispersion (Ion Power LQ-1115) was used to fabricate Nafion films. LQ-1115 
is a 15% wt. Nafion dispersion in alcohols and H2O. Casting of the dispersion and 
evaporation of alcohols generates a Nafion film. Addition of AgNO3 to the mixture 
resulted in cracking of the Nafion film after drying. Glycerol was added to the mixture to 
prevent film cracking. With glycerol it was determined empirically that 3 mM was the 
highest AgNO3 concentration that could be used without the resulting film cracking after 
drying. After drying the resultant film is soft due to the glycerol and should not be 
mechanically disturbed. After the addition of glycerol it is unknown if the reverse micelle 
nanostructure of Nafion is maintained. Although the resultant Nafion film is stable for at 
least a day, extended storage resulted in spontaneous colour change likely due to the 
photoreactivity of silver. The measured wells were spaced out leaving an empty well 
surrounding every well being measured (eg. Figure 2.4-2). This was done to minimize the 
chance of interference from H2S diffusion from an adjacent well. As a result a 96-well 
plate could only measure a maximum of 24 different wells using our procedure. 
 2.5.2 Optical Properties 
After casting, the resulting Ag-containing Nafion film is transparent and does not alter 
the absorbance properties of the microplate cover (Figure 2.4-4). After exposure to H2S a 
brown colour develops. Due to the design of the assay only gaseous H2S will come in 
contact and react with the silver to produce a colour change. As expected other 
commonly used thiols in biochemistry do not produce a reaction and colour change 
(Figure 2.4-3). Ag2S nanoparticles produce very strong absorbance in the 200-300 nm 
range and broad absorbance tail [244]. The spectra produced after exposure to 100 µM 
Na2S is consistent with Ag2S nanoparticle formation. Although absorbance at 200-300 
nm would allow the highest sensitivity to Ag2S formation, the polystyrene microplate 
used absorbs light in this spectral range (Figure 2.4-4). Measurement at 310 nm was 
chosen as a compromise between maximizing detection, and minimizing interference 
from the microplate cover, and possibly biomolecules, for example amino acids and 
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nucleic acids absorb light in the sub-300 nm range. Due to measurement at 310 nm real-
time measurements are also limited by the turbidity of the sample. Turbid samples cannot 
be measured in real-time using our assay system since the absorbance of the solution is 
measured simultaneously, however they can be measured in an end-point manner.  
 2.5.3 Limit of Detection and Linear Range 
The limit of detection (LOD) of the assay was determined according to the EP17 
guideline published by the National Committee for Clinical Laboratory Standards 
(NCCLS) [248, 249]. The LOD was calculated to be 2.61 nmol (8.70 µM), and the linear 
range of the assay was from 2.61 nmol (8.70 µM) to 30 nmol (100 µM) (Figure 2.4-5). 
Larger concentration samples may produce lower absorbances (Figure 2.4-3) than 100 
µM. When this occurred the colour of the reacted Nafion was not uniform and a dark ring 
was produced (Figure 2.4-2). Although the spots at concentrations greater than 100 µM 
appeared darker, a lower absorbance was measured. The LOD of 8.7 µM does not allow 
measurement of H2S in biological samples without adding substrate to stimulate H2S 
production. 
 2.5.4 CSE Enzyme Assay 
To test the assay, the kinetic parameters of the enzyme CSE were determined using L-
cysteine as a substrate, and compared to the literature values. CSE activity was measured 
in real-time, the V0 was calculated from the slopes, and fit into the Michaelis-Menten 
equation using the Solver function in Microsoft Excel. A KM of 11.13 ± 0.57 mM was 
calculated and a Vmax of 0.45 ± 0.01 nmol min
-1. Although the Vmax is very close to the 
Vmax determined by Faccenda et al. (0.37 ± 0.02 nmol min
-1) [185], the KM differs from 
previously determined values. Previously obtained KM values are 3.79 ± 2.07 mM using 
the PDMS-based DTNB method used by Faccenda et al. [185], and 2.75 mM, using the 
methylene blue method [81]. This is somewhat different from the KM value determined 
using our colourimetric assay. The discrepancy could be due to our rates being a 
combination of enzymatic H2S production, and H2S volatilization. The enzymatic curves 
generated do not represent normal enzymatic activity where after steady-state kinetics the 
enzymatic activity decreases over time, and instead in our curves the enzyme activity 
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appears to increase over time until after ~1700 s (Figure 2.4-6). The tail end of each 
curve, from 1900 s to 2400 s, was used for V0 calculations, in order to differentiate 
between the different substrate concentrations. The initial apparent increase in enzymatic 
activity is likely due to the establishment of equilibrium between H2S production and 
volatilization. Although described as “real time” [250], the assay could perhaps be more 
accurately described as “near real-time”. 
The kcat for CSE catalysis of cysteine was been reported as 0.4 s
-1 by Sun et al. 
[81], and 3.26 s-1 by Faccenda et al. [185]. Based on the enzyme concentration used in 
our assay, volume of solution used in our assay, and the kcat determined by Sun et al. it 
was calculated that, after 1900 s, a total of 5.8 nmol (19 µM) H2S has formed. Using the 
kcat value determined by Faccenda et al. the total H2S formed after 1900 s was calculated 
to be 47 nmol (1.6 x 102 µM). These values are 1-2 orders of magnitude lower than the 
lowest cysteine concentration tested (4.0 mM). The steady-state assumption, that the 
concentration of the enzyme-substrate complex ([ES]) does not change, is likely true 
even after 1900 s (~31 min) from the start of the enzyme assay. 
2.5.5 Mouse Liver Homogenate H2S Production 
Mouse liver homogenate H2S production was measured using an endpoint variation of the 
microplate assay. As commonly done in the literature, H2S production was stimulated by 
the addition of L-cysteine under aerobic conditions. Using 5 mM cysteine, mouse liver 
homogenate H2S production was determined to be 4.89 ± 0.19 nmol min
−1 mL−1 
homogenate. Furne et al. measured H2S production from mouse liver homogenate at 
3.210 ± 0.162 nmol min−1 mL−1 using 10 mM L-cysteine and the polarographic H2S 
sensor, a method specific to H2S gas [167]. Using our assay system we were able to 
obtain similar values. 
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 2.5.6 Possible Improvements in Assay Design 
The design of the assay may be improved by allowing the Ag-containing Nafion to be in 
contact with the solution, but separated by a gas-permeable membrane. The Nafion and 
gas-permeable membrane could be moved to the bottom of the well plate. This might 
eliminate some of the lag during real-time measurements. The use of Ag could also be 
eliminated altogether, and replaced with a fluorescent probe. Fluorescence measurements 
are generally more sensitive than absorbance, and a significant decrease in detection limit 
would be expected if this could be accomplished. 
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2.6 Conclusions 
In this chapter we developed a method for measuring H2S in biological samples. By 
coating the bottom of a microplate cover with Nafion polymer mixed with AgNO3 a 
simple colourimetric assay for measuring H2S in 96-well plates was developed. The assay 
has a limit of detection of 8.7 µM, which is similar to the methylene blue method, and is 
linear up to 100 µM. As a demonstration of the assay, the kinetic parameters of CSE 
enzyme were measured, as well as H2S production from mouse tissue homogenate in the 
presence of cysteine. Our assay is simple, inexpensive, and specific to H2S gas. Although 
some limitations of the assay exist, they offer opportunity for improvement. 
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CHAPTER 3 
 
REACTIONS OF H2S WITH PROTEIN THIOLS AND S-SULFURATION OF GAPDH 
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3.1 Introduction 
In this chapter we investigated the reactivity of H2S with protein thiols. H2S was 
previously discovered to mediate biological activity by post-translational modification of 
cysteine residues (S-sulfuration). The first protein discovered to be modified by H2S was 
GAPDH [141]. In the original publication, purified GAPDH was S-sulfurated at Cys 152. 
The site of S-sulfuration was detected by mass spectrometry. When analyzed in cells, 
~30% of GAPDH was S-sulfurated under basal conditions, determined by the modified 
biotin shift assay. Many other proteins, including actin and tubulin, have been shown to 
be S-sulfurated at high proportions. Massive basal S-sulfuration of proteins like actin and 
tubulin does not support H2S’s role as a gasotransmitter, since a gasotransmitter by 
definition requires specific molecular targets [5]. Given that the levels of H2S in tissues 
are in the nM range [167], it also raises the question of whether H2S production is high 
enough to cause mass S-sulfuration of proteins. The modified biotin shift assay has 
recently been shown to be non-specific to S-sulfuration [142], and it is possible the high 
basal S-sulfuration of proteins is an artifact. 
 GAPDH is an important glycolysis enzyme with additional functions continually 
being discovered [251-253]. GAPDH contains three cysteine residues, Cys 152, Cys 156, 
and Cys 247. Some authors use a numbering system that maximizes the sequence 
homology between organisms where N-terminal residues are ignored, and the conserved 
residues are aligned [252]. Under this numbering system Cys 152 would be labeled as 
Cys 149. Mustafa et al. refer to this cysteine as Cys 150 [141]. Cys 152 is the active site 
catalytic cysteine residue, which attacks the substrate glyceraldehyde 3-phosphate [252]. 
A reduced Cys 152 is required for GAPDH activity, and oxidation of Cys 152 can abolish 
catalytic activity [253]. This raises the question of whether H2S can react with the free 
Cys 152 on GAPDH and S-sulfurate it. The sulfurs in a free cysteine and in H2S are in 
their most reduced states (-2), and a direct reaction with no additional oxidants is 
impossible [161]. 
 The initial redox state of GAPDH was not explored in the initial publication; 
however it is an important consideration for the redox modification of biomolecules. We 
tested the possibility whether H2S can react with reduced cysteines (-SH), cysteine 
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disulfides (-S-S-), or perhaps another oxidized form of cysteine (-SOH, -SNO). Work by 
Francoleon et al. has shown evidence that at low H2S concentrations S-sulfuration can 
occur, while at higher H2S concentrations, the excess H2S can reduce the S-sulfurated 
protein thiols [162]. This is an interesting theory that has been considered in this work. 
Polysulfides are gaining recognition in recent years as important H2S-derived 
biomolecules [34]. It may be possible for polysulfides to react with reduced cysteine 
thiols to S-sulfurate proteins. We have explored the S-sulfurating ability of polysulfides, 
as well as NaSH.  
 In this chapter, when analyzed by mass spectrometry, GAPDH was derivatized 
with excess iodoacetamide after treatments to yield carbamidomethylated persulfide 
derivatives (R-S-S-CH2-CO-NH2). This was done in order to help differentiate S-
sulfuration from sulfinic acid formation. Depending on mass accuracy of an instrument, 
unmodified R-S-SH may be erroneously assigned to R-S-O2H due to very similar masses.  
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3.2 Materials 
3.2.1 Reagents 
Sodium sulfide (161527), potassium polysulfide (12665), oxidized glutathione (G4376), 
BSA (A9647), NAD+ (N7004), sodium arsenate (A6756), glyceraldehyde 3-phosphate 
barium salt (G5376), iodoacetamide (I1149), sinapinic acid (D7927), N-ethylmaleimide 
(E3876), α-cyano-4-hydroxycinnamic acid (476870), vasopressin (V0377) were 
purchased from Sigma-Aldrich. NaCl (S2830) was purchased from ACP Chemicals. 
Dithiothreitol (DTT) (100597) was purchased from MP Biomedicals. ZebaTM desalting 
columns (89882) and tris base (BP152-1) were purchased from Fisher Scientific. C18 Zip 
Tips® (ZTC18S096) were purchased from Millipore. Sequencing grade trypsin (V511A) 
was purchased from Promega. 
 3.2.2 H2O Purity 
Terrific broth for growing E. coli was made with distilled H2O. All other aqueous 
solutions were made using Milli-Q H2O.  
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3.3 Methods 
3.3.1 Vasopressin Treatments and Mass Spectrometry 
1 µM vasopressin was diluted to 200 nM with pH 7.4 100 mM sodium phosphate buffer. 
Polysulfides in buffered solution were added to vasopressin in a 1:1 ratio. The solutions 
were incubated 30 min at 37 °C, and purified with Millipore Zip Tips® according to 
manufacturer protocol. Samples were diluted 1 part sample with 3 parts Milli-Q H2O. 1 
µL of sample was spotted with 1 µL of 10 mg/mL matrix solution (α-cyano-4-
hydroxycinnamic acid in 60 % acetonitrile, 0.1 % trifluoroacetic acid) on a MALDI plate 
and analyzed by an Applied Biosystems Voyager DE-Pro mass spectrometer in reflector 
mode. 
3.3.2 Polysulfide Concentration 
Since polysulfides exist in equilibrium as a mixture of species, the concentration of 
polysulfides used was estimated. Since potassium polysulfide (12665) is ≥42% K2S, 
polysulfide concentrations were calculated based on the assumption of 100% K2S. This 
over-estimates polysulfide concentrations as the presence of larger molecular weight 
polysulfides will reduce the molarity of the solution.   
3.3.3 GAPDH Assay Buffer Handling 
GAPDH assay buffer (20 mM Tris pH 7.8, 100 mM NaCl, 1 mM NAD+, 10 mM sodium 
pyrophosphate, 20 mM sodium arsenate, and 0.1 mg/mL BSA) was made fresh weekly. 
Unused buffer was stored in at 4 °C in the dark. When performing the GAPDH assay, an 
aliquot of the buffer were taken out to be pre-warmed at 37 °C. After completion of an 
enzymatic assay any leftover pre-warmed buffer was discarded and not re-used. Milli-Q 
H2O was used for buffer preparation.  
 3.3.4 Glyceraldehyde 3-Phosphate Preparation 
Glyceraldehyde 3-phosphate (G3P) which was prepared from the barium salt according 
to the manufacturer protocol (Sigma G5376). After preparation the concentration of G3P 
was quantified using a standard colourimetric phosphate assay using molybdate. Aliquots 
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of G3P were stored at -20 °C. After thawing of an aliquot of G3P for use in the GAPDH 
enzyme assay any remaining G3P in the aliquot was not re-used and discarded. 
3.3.5 GAPDH Purification 
BL21(DE3) E. coli containing a pET15b vector expressing wild-type His-tagged human 
GAPDH, as well as a second cell stock expressing the C156S mutant, was kindly 
provided by Dr. Ann English (Concordia University). 1 L of Terrific broth containing 0.1 
mg/mL ampicillin was inoculated with cells grown from an overnight pre-culture. Cells 
were grown at 37 °C until OD600 reached 0.4 to 0.6, at which point expression was 
induced by addition of 0.4 mM (final concentration) isopropyl β-D-1-
thiogalactopyranoside (IPTG). Cells were grown for a further 4 h, pelleted by 
centrifugation (3950 g, 30 min, 4 °C), supernatant was discarded and cell pellets were 
frozen overnight at -84 °C. Cells were resuspended in lysis buffer (50 mM sodium 
phosphate pH 8.0, 300 mM NaCl, 10 mM imidazole, 2 mM PMSF, 1 mM DTT, 100 
µg/mL lysozyme, 50 µg/mL DNase I, 0.2% Triton X100), incubated on ice for 30 min, 
lysed by sonication, and centrifuged (11300 g, 30 min, 4 °C). The supernatant was 
purified using a nickel affinity column (Sigma P6611) strictly following the manufacturer 
protocol published by Sigma-Aldrich. The protein was buffer exchanged into storage 
buffer (50 mM Tris 1 mM DTT pH 7.4) using a centrifugal filter (Millipore UFC903008), 
following manufacturer protocol. 2 M sorbitol (cryoprotectant) was added, and aliquots 
were stored at -84 °C. 
3.3.6 Reduced GAPDH Enzyme Assay 
GAPDH was buffer exchanged using desalting columns (Fisher 89882) into 20 mM Tris 
pH 7.8 before each trial. NaSH and PS stock solutions were diluted in 20 mM Tris pH 7.8 
immediately before addition to GAPDH (0.5 µg/µL), and were added at a 1:1 volume 
ratio. GAPDH was incubated with NaSH or PS for 30 min at 37 °C. For the control 
untreated enzyme, buffer was used instead of NaSH or PS. 0.5 µg of the enzyme was 
added to 500 µL of assay buffer (20 mM Tris pH 7.8, 100 mM NaCl, 1 mM NAD+, 10 
mM sodium pyrophosphate, 20 mM sodium arsenate, and 0.1 mg/mL BSA). Buffer was 
pre-warmed at 37 °C before measurements. Reaction was initiated by the addition of 
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glyceraldehyde 3-phosphate (G3P), which was previously prepared from the barium salt 
according to manufacturer protocol (Sigma G5376). The conversion of NAD+ to NADH 
was quantified by measuring absorbance at 340 nm with an Agilent 8453 UV/vis 
spectrophotometer equipped with a temperature controller set at 37 °C. Measurements 
were started immediately after the addition of G3P, and each sample was measured for 
120 s. The treated GAPDH enzyme samples were stored on ice while waiting to be 
measured. A single set of different concentration samples was measured first, following a 
replicate set of the same samples, and a second replicate of the same samples, ie. the 
same concentration sample was not measured three times back-to-back.  
3.3.7 Oxidized GAPDH Enzyme Assay 
In the GSSG-oxidized GAPDH assay, GAPDH, in 20 mM Tris pH 7.8 was treated with 
equal-volume GSSG (10 mM in 20 mM Tris pH 7.8) for 1 h at room temp. The GAPDH 
assay was continued with buffer exchange, NaSH, PS, or DTT treatments, same as 
reduced GAPDH assay above. In the H2O2-oxidized GAPDH assay, GAPDH, in 20 mM 
Tris pH 7.8 was treated with equal-volume H2O2 (200 µM) for 30 min at room temp. The 
GAPDH assay was continued with NaSH, PS, or DTT treatments, same as reduced 
GAPDH assay above. In the GSNO-oxidized GAPDH assay, GAPDH, in 20 mM Tris pH 
7.8 was treated with equal volume GSNO (1 mM in 20 mM Tris pH 7.8) for 30 min at 37 
°C in the dark. The GAPDH assay was continued with buffer exchange, NaSH or PS 
treatments, same as reduced GAPDH assay above, except NaSH and PS treatments were 
done in the dark. 
3.3.8 GAPDH Preparation and Digestion for Mass Spectrometry 
Reduced wild-type GAPDH, or reduced C156S mutant GAPDH, or GSSG-treated 
GAPDH was prepared and treated with NaSH or PS using the same conditions as per 
enzyme assay. For the control untreated enzyme, buffer was used instead of NaSH or PS. 
GAPDH was then treated with equal volume 40 mM iodoacetamide in 20 mM Tris pH 
7.8 for 2 h at room temperature in the dark. Enzyme was buffer exchanged using 
desalting columns into 50 mM ammonium bicarbonate (pH 8.0). Trypsin was added in a 
10:1 protein to protease ratio, and GAPDH was digested overnight at 37 °C. GAPDH 
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tryptic digest was desalted using Millipore Zip Tips® according to manufacturer 
protocol. 
To analyze GSNO-treated GAPDH a differential labeling protocol was used [24]. 
First GAPDH was treated with GSNO, then NaSH or PS, as per the oxidized enzyme 
assay. For the untreated control enzyme, buffer was used instead of NaSH or PS. After 
NaSH or PS treatment, GAPDH was treated with 20 mM iodoacetamide (from 200 mM 
stock in 20 mM Tris pH 7.8) for 2 h at room temperature in the dark. GAPDH was buffer 
exchanged into 100 mM sodium phosphate pH 7.0 using desalting columns. 10 mM 
sinapinic acid (from 200 mM stock in DMSO), and 20 mM N-ethylmaleimide (from 320 
mM stock in Milli-Q H2O) was added to GAPDH and the enzyme was incubated for 3 h 
at room temperature in the dark. GAPDH was buffer exchanged using desalting columns 
into 50 mM ammonium bicarbonate (pH 8.0) and trypsin digested overnight at 37 °C 
using a 10:1 protein to protease ratio. GAPDH tryptic digest was desalted using Millipore 
Zip Tips® according to manufacturer protocol. 
3.3.9 Mass Spectrometry 
Samples were analyzed using a Waters SYNAPT G2-Si mass spectrometer configured 
for nano-Electrospray ionization operated in positive mode coupled to a Waters 
nanoACQUITY UPLC system.  The UPLC was configured for 1D single pump trapping 
with a Waters ACQUITY UPLC Symmetry C18 2G V/M trap column coupled with a 
Waters ACQUITY Peptide BEH C18. Mobile phase buffer A was 0.1% formic acid. 
Mobile phase buffer B was acetonitrile 0.1% formic acid. Samples were loaded on the 
trap column for 3 min at a flow rate of 5 µL/min in 97% buffer A. 60 min gradient was 
run at a flow rate of 0.5 µL/min where buffer A concentration was 97% at 0 min to 65% 
at 30 min, 40% at 35 min, 15% at 36 min, 15% at 41 min, and 97% at 42 min. All 
samples were first analyzed in MSe mode, followed by MS/MS sequencing. Reduced and 
GSSG-oxidized samples were analyzed using DDA MS/MS mode. The DDA acquisition 
method for MS/MS used an include list of theoretical m/z values for precursor ions 
matching the possible modifications of cys-containing peptides based on sulfide, 
iodoacetamide, and glutathione treatments. GSNO-oxidized and C156S mutant samples 
were analyzed by targeted MS/MS of precursor ions from MSe acquisitions. 
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3.3.10 Molecular Dynamics (MD) Simulations 
All structure preparation and MD calculations were performed using the Molecular 
Operating Environment 2013 (MOE) program [25]. A high-resolution (1.75 Å) X-ray 
crystal structure of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) complexed 
with NAD+, from Homo sapiens, was obtained from the Protein Data Bank (PDB ID: 
1U8F) [26]. The structure was then protonated using the default propKa [25, 27] method 
in MOE, and all water molecules were removed except those in or near the catalytic and 
ligand binding sites. The resulting complex was then solvated with water to four layers 
deep. Exploiting the fact that GAPDH is a homo-tetramer, Cys156 of chain B (Cys156B) 
was mutated to include a persulfide (-SSH) moiety, while Cys156 of chain A was 
maintained in its wild-type thiol (-SH) state. The entire solvated complex was then 
optimized (energy minimized) using the molecular mechanics AMBER12EHT force field 
until the root mean square gradient of the total energy fell below 0.21 kJ mol-1 Å-1. The 
MM optimized structure was then used as a starting structure for subsequent MD 
simulations in which a standard protocol was used. More specifically, the complex 
underwent an equilibration period in which temperature was gradually raised from 150 K 
to 300 K over a period of 100 ps. This was then followed by a 10 ns production MD in 
which the temperature was held at 300 K. A cluster analysis was then performed, and the 
median of the most populated cluster was chosen as the average structure. These analyses 
were performed separately on both chain A (-SH) and B (-SSH). The average structures 
of these two chains were superimposed and analyzed to find the effect of the mutation on 
GAPDH. 
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3.4 Results 
3.4.1 S-sulfuration of Vasopressin 
Vasopressin was used as a model peptide for studying S-sulfuration. Vasopressin ionizes 
well in MALDI-MS. Vasopressin has an amino sequence of GRPCNQFYC and forms an 
internal disulfide between the cysteines. Vasopressin was reacted with varying 
concentrations of polysulfides and NaSH. Figure 3.4.1-1 shows the spectra of vasopressin 
after reaction with increasing amounts of polysulfides relative to vasopressin. S-
sulfuration of vasopressin is first observed at ~1,000 fold polysulfides where a singly S-
sulfurated vasopressin peptide (m/z 1117) is visible. Relative intensity of the S-sulfurated 
peptide is ~10% of the unmodified (m/z 1084). At ~10,000 fold polysulfides the singly S-
sulfurated vasopressin (m/z 1117) is now more intense at ~18% of the unmodified (m/z 
1084). Doubly S-sulfurated (m/z 1150) vasopressin appears at ~10,000 fold polysulfide 
concentration and the relative intensity compared to the unmodified is ~8%. Higher 
concentrations of polysulfides produced more S-sulfuration; however the modification is 
in low stoichiometry compared to the unmodified peptide. NaSH produced the same 
results as polysulfides, requiring ~1,000 fold NaSH to observe S-sulfuration. To test the 
possibility that the disulfide in vasopressin is reforming, vasopressin was reacted with 
iodoacetamide to trap the cysteine persulfide. Blocking with iodoacetamide did not 
increase the relative amount of S-sulfuration detected. An example spectrum is included 
in Appendix A. m/z 1107 and m/z 1123 are unknown derivatives of vasopressin present 
in the purchased product. 
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Figure 3.4.1-1 MALDI-MS spectra of vasopressin treated with A) 10 fold (10 µM) 
polysulfides B) 100 fold (100 µM) polysulfides C) 1,000 fold (1 mM) polysulfides D) 
10,000 fold polysulfides (10 mM). m/z 1084 represents unmodified vasopressin, m/z 
1117 represents vasopressin with a single S-sulfurated cysteine, m/z 1150 represents 
vasopressin with two S-sulfurated cysteines.  
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 3.4.2 Reduced GAPDH Activity and Analysis by Mass Spectrometry 
The activity of the reduced GAPDH enzyme was measured with and without treatment 
with 50 µM NaSH. 50 µM NaSH had no effect on the kinetic parameters of GAPDH 
(Figure 3.4.2-1). The control enzyme had a KM of 0.35 ± 0.03 mM and a Vmax of 51 ± 5 
µM/min. After NaSH treatment the KM was 0.30 ± 0.03 mM, and the Vmax was 52 ± 6 
µM/min. Reduced GAPDH enzyme activity was tested with increasing concentrations of 
NaSH and polysulfides. NaSH produced a small, however statistically insignificant, 
change in enzyme activity while polysulfides produced a decrease in enzymatic activity 
to a minimum of ~42% of untreated enzyme at 200 µM polysulfides (Figure 3.4.2-2).  
50 µM NaSH or polysulfides was used to treat the enzyme before mass 
spectrometry. Peptides were labeled with iodoacetamide to trap the persulfide. It was 
found that after treatment with NaSH Cys 247 was S-sulfurated, however Cys 152 and 
Cys 156 were not (Table 3.4.2-1). After treatment with polysulfides Cys 247 and Cys 156 
were S-sulfurated, however the active site residue Cys 152 was not (Table 3.4.2-1) 
(Figure 3.4.2-3). S-sulfuration of Cys 156 correlates with a decrease in enzyme activity, 
while S-sulfuration of Cys 247 appears to have no change in enzymatic activity. 
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Figure 3.4.2-1 (A) Michaelis-Menten kinetics of purified GAPDH enzyme (KM = 0.35 ± 
0.03 mM, Vmax = 51 ± 5 µM/min). (B) Michaelis-Menten kinetics of purified GAPDH 
enzyme treated with 50 µM NaSH (KM = 0.30 ± 0.03 mM, Vmax = 52 ± 6 µM/min). The 
error bars represent standard error (n=3). Adapted from [254] with permission.  
 
 
 
 
 
 
 
 62 
 
 
Figure 3.4.2-2 (A) Enzymatic activity of purified GAPDH (1 µg/mL) as a function of 
increasing sodium hydrosulfide concentration. (B) Enzymatic activity of purified 
GAPDH (1 µg/mL) as a function of increasing polysulfide concentration. The error bars 
represent standard error (n=3). Adapted from [254] with permission. 
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Figure 3.4.2-3 (A) MS/MS spectrum of active site peptide (m/z 918.00) from control 
GAPDH enzyme. (B) MS/MS spectrum of active site peptide (m/z 933.43) from 
polysulfide treated GAPDH enzyme. The mass of y ions after y7 increases by 32 Da 
indicating additional sulfur on Cys 156. The mass difference between y10 and y11 does not 
change indicating Cys 152 is unchanged. CAM denotes carbamidomethyl group after 
iodoacetamide treatment. Adapted from [254] with permission. 
 
 
 64 
 
Table 3.4.2-1 Cysteine-containing tryptic peptides sequenced by ESI-MS/MS analysis of 
purified GAPDH enzyme: reduced control, treated with sulfide (NaSH), treated with 
polysulfides (PS). Adapted from [254] with permission.  
Treatments Sequence Modification Cysteine Precursor 
ion m/z
a
 
IAM VPTANVSVVDLTCR -S-CAM 247 765.90 
IISNASCTTNCLAPLAK -S-CAM 152 917.46 
-S-CAM 156 
NaSH 
IAM 
VPTANVSVVDLTCR -S-CAM 247 765.91 
VPTANVSVVDLTCR -S-S-CAM 247 781.89 
IISNASCTTNCLAPLAK -S-CAM 152 917.48 
-S-CAM 156 
PS 
IAM 
VPTANVSVVDLTCR -S-CAM 247 766.44
b
 
VPTANVSVVDLTCR -S-S-CAM 247 782.43
b
 
IISNASCTTNCLAPLAK -S-CAM 152 917.49 
-S-CAM 156 
IISNASCTTNCLAPLAK -S-CAM 152 933.46 
-S-S-CAM 156 
a 
All precursor ions reported are +2 ions unless otherwise indicated in () beside the m/z. 
b
 
13
C isotope ion. 
Abbreviations:
 
CAM, carbamidomethyl; IAM, iodoacetamide; PS, polysulfide. 
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3.4.3 GSSG-Oxidized GAPDH Activity and Mass Spectrometry Analysis 
GAPDH was oxidized with GSSG to form glutathionylated GAPDH. The amount of 
GSSG was chosen with intent to produce approximately 50% reduction in enzyme 
activity, in order to observe a possible decrease or increase in enzymatic activity. A plot 
of enzyme activity with increasing GSSG concentration is included in Appendix A. 
During enzyme activity experiments 5 mM GSSG produced a larger decrease in 
enzymatic activity than anticipated; the enzyme retained approximately 25% activity 
compared to the untreated control (Figure 3.4.3-1). After treatment with DTT, the 
GAPDH enzymatic activity increased to ~70% of untreated control at 100 µM DTT 
(Figure 3.4.3-1A). Increasing the DTT concentration past 100 µM produced no further 
increase in enzymatic activity. NaSH treatment produced very similar results; activity 
increased to approximately ~60% of untreated control at 100 µM NaSH, and to ~70% of 
untreated control at 500 µM (Figure 3.4.3-1B). After polysulfide treatment, activity 
increased to approximately ~55% of untreated control at 100 µM and 65% of untreated 
control at 500 µM (Figure 3.4.3-1C). After mass spectrometry analysis glutathionylated 
Cys 247 was detected (m/z 889.92) (Table 3.4.3-1). NaSH treatment caused S-sulfuration 
of Cys 247 (m/z 781.92), while polysulfide treatment caused S-sulfuration of Cys 247 
(m/z 781.88) and Cys 156 (m/z 933.46).  
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Figure 3.4.3-1 (A) Enzymatic rate of purified wild-type GAPDH (1 µg/mL), GSSG-
treated, as a function of increasing DTT concentration. (B) Enzymatic rate of purified 
wild-type GAPDH (1 µg/mL), GSSG-treated, as a function of increasing NaSH 
concentration. (C) Enzymatic rate of purified wild-type GAPDH (1 µg/mL), GSSG-
treated, as a function of increasing polysulfide (PS) concentration. The error bars 
represent standard error (n=3). Rate is expressed as percentage of untreated control. 
Adapted from [254] with permission. 
 
 
 
 
 
 
 67 
 
Table 3.4.3-1 Cysteine-containing tryptic peptides sequenced by ESI-MS/MS analysis of 
purified GAPDH enzyme: GSSG-treated control, GSSG-treated and treated with sulfide 
(NaSH), GSSG-treated and treated with polysulfides (PS). Adapted from [254] with 
permission. 
Treatments Sequence Modification Cysteine Precursor 
ion m/z
a
 
GSSG 
IAM 
VPTANVSVVDLTCR -S-H 247 737.39 
VPTANVSVVDLTCR -S-CAM 247 765.91 
VPTANVSVVDLTCR -S-S-Glu 247 889.92 
VPTANVSVVDLTCR -S-S-Glu 247 593.61 
(+3) 
IISNASCTTNCLAPLAK -S-CAM 152 917.46 
-S-CAM 156 
GSSG 
NaSH 
IAM 
VPTANVSVVDLTCR -S-H 247 737.39 
VPTANVSVVDLTCR -S-CAM 247 765.93 
VPTANVSVVDLTCR -S-S-CAM 247 781.92 
VPTANVSVVDLTCR -S-S-Glu 247 889.95 
IISNASCTTNCLAPLAK -S-CAM 152 888.95 
-S-H 156 
GSSG 
PS 
IAM 
VPTANVSVVDLTCR -S-H 247 737.39 
VPTANVSVVDLTCR -S-CAM 247 765.90 
VPTANVSVVDLTCR -S-S-CAM 247 781.88 
VPTANVSVVDLTCR -S-S-Glu 247 889.94 
VPTANVSVVDLTCR -S-S-Glu 247 593.62 
(+3) 
IISNASCTTNCLAPLAK -S-H 152 or 156 888.96 
-S-CAM 152 or 156 
IISNASCTTNCLAPLAK -S-CAM 152 917.49 
-S-CAM 156 
IISNASCTTNCLAPLAK -S-CAM 152 933.46 
-S-S-CAM 156 
a 
All precursor ions reported are +2 ions unless otherwise indicated in () beside the m/z.
 
Abbreviations: CAM, carbamidomethyl; Glu, glutathione; GSSG, glutathione disulfide; 
IAM, iodoacetamide; PS, polysulfide. 
 
 
 
 
 
 
 
 
 68 
 
3.4.4 H2O2-Oxidized GAPDH Activity 
GAPDH was oxidized with H2O2 to form sulfenic acid (-SOH) derivatives of cysteine, 
and perhaps higher oxidation state sulfinic acid (-SO2H), and sulfonic acid (-SO3H). H2O2 
concentration was chosen to produce ~50% inactivation. After treatment with DTT an 
increase from ~35% of untreated control to ~60% of untreated control was observed with 
the lowest concentration tested of 5 µM (Figure 3.4.4-1A). Additional concentration of 
DTT did not increase activity past ~60% of control. Treatment with 5 µM NaSH 
increased GAPDH activity from ~45% to ~60% of untreated control with no further 
increase observed (Figure 3.4.4-1B). Treatment with polysulfides did not significantly 
alter the activity of H2O2-oxidized GAPDH (Figure 3.4.4-1C). 
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Figure 3.4.4-1 (A) Enzymatic rate of purified wild-type GAPDH (1 µg/mL), H2O2-
treated, as a function of increasing DTT concentration. (B) Enzymatic rate of purified 
wild-type GAPDH (1 µg/mL), H2O2-treated, as a function of increasing NaSH 
concentration. (C) Enzymatic rate of purified wild-type GAPDH (1 µg/mL), H2O2-
treated, as a function of increasing polysulfide (PS) concentration. The error bars 
represent standard error (n=3). Rate is expressed as percentage of untreated control. 
Adapted from [254] with permission. 
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3.4.5 GSNO-Oxidized GAPDH Activity and Mass Spectrometry Analysis 
GAPDH was pre-treated with GSNO to test whether S-nitrosation may affect the S-
sulfuration of GAPDH. Both NaSH and polysulfides produced a biphasic response where 
activity initially decreased with increasing sulfide concentration, but later increased as 
sulfide concentration was increased past 50 µM (Figure 3.4.5-1). NaSH treatment 
decreased GAPDH activity from ~55% of untreated control to ~40% of untreated control 
at 50 µM NaSH (Figure 3.4.5-1A). At 200 µM NaSH activity increased to ~80% of 
untreated control. After 50 µM polysulfide treatment, GAPDH activity decreased from 
~70% of untreated control to ~20% of untreated control (Figure 3.4.5-1B). Increasing 
polysulfide concentration to 500 µM produced ~60% activity relative to untreated 
control.  
 Peptides were labeled for mass spectrometry using a differential labeling protocol. 
Free thiols were first reacted with iodoacetamide, sinapinic acid was used to de-nitrosate 
S-nitrosothiols and N-ethylmaleimide was used to label de-nitrosated cysteine residues. 
Using this protocol, S-sulfurated cysteines will be trapped with iodoacetamide, while S-
nitrosated cysteines will be labeled with N-ethylmaleimide. After GSNO treatment Cys 
247, Cys 152, and Cys 156 were found labeled with N-ethylmaleimide, indicating S-
nitrosation (Table 3.4.5-1). Cys 152 reacted with carbamidomethyl was also sequenced 
(m/z 951.48), indicating a free thiol, while Cys 156 was only detected labeled with N-
ethylmaleimide. After NaSH and polysulfide treatments the same set of peptides were 
sequenced as the control (Table 3.4.5-1). No S-sulfuration was detected.  
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Figure 3.4.5-1 (A) Enzymatic rate of purified wild-type GAPDH (1 µg/mL), GSNO-
treated, as a function of increasing NaSH concentration. (B) Enzymatic rate of purified 
wild-type GAPDH (1 µg/mL), GSNO-treated, as a function of increasing polysulfide 
(PS) concentration. The error bars represent standard error (n=3). Rate is expressed as 
percentage of untreated control. Adapted from [254] with permission. 
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Table 3.4.5-1 Cysteine-containing tryptic peptides sequenced by ESI-MS/MS analysis of 
purified GAPDH enzyme, control GSNO, GSNO-treated and treated with sulfide 
(NaSH), GSNO-treated and treated with polysulfide (PS). Adapted from [254] with 
permission. 
Treatments Sequence Modification Cysteine Precursor 
ion m/z
a
 
GSNO 
IAM 
SA 
NEM 
VPTANVSVVDLTCR -S-NEM 247 799.91 
IISNASCTTNCLAPLAK -S-CAM 152 951.48 
-S-NEM 156 
IISNASCTTNCLAPLAK -S-NEM 152 985.49 
-S-NEM 156 
GSNO 
NaSH, 
IAM,  
SA  
NEM 
VPTANVSVVDLTCR -S-H 247 737.39 
VPTANVSVVDLTCR -S-NEM 247 799.91 
IISNASCTTNCLAPLAK -S-CAM 152 951.48 
-S-NEM 156 
IISNASCTTNCLAPLAK -S-NEM 152 985.49 
-S-NEM 156 
GSNO 
PS  
IAM  
SA  
NEM 
VPTANVSVVDLTCR -S-NEM 247 799.91 
IISNASCTTNCLAPLAK -S-CAM 152 951.48 
-S-NEM 156 
IISNASCTTNCLAPLAK -S-NEM 152 985.49 
-S-NEM 156 
a 
All precursor ions reported are +2 ions unless otherwise indicated in () beside the m/z. 
Abbreviations: CAM, carbamidomethyl; GSNO, S-nitrosoglutathione; IAM, iodoacetamide; 
NEM, N-ethylmaleimide; SA, sinapinic acid; PS, polysulfide. 
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3.4.6 C156S Mutant GAPDH Activity and Mass Spectrometry Analysis 
A C156S mutant of GAPDH was used to test whether it was possible to S-sulfurate Cys 
152, and what effect the modification has on enzymatic activity. It was found the C156S 
mutant of GAPDH had the same kinetic parameters, within experimental error, as the 
wild-type enzyme (KM = 0.23 ± 0.08 mM, Vmax = 49 ± 8 µM/min) (Figure 3.4.6-1). After 
NaSH treatment the activity of C156S GAPDH gradually decreased to 70% of untreated 
enzyme at 500 µM NaSH (Figure 3.4.6-2A). Treatment with 10 µM polysulfides caused a 
drop in C156S GAPDH activity to 25% of untreated control (Figure 3.4.6-2B). Increasing 
polysulfide concentration past 100 µM caused an increase in enzymatic activity.  
 Mass spectrometry confirmed the mutation of cysteine 156 to a serine. After 
NaSH or polysulfide treatments S-sulfuration of active site Cys 152 was detected (m/z 
896.95) (Table 3.4.6-1). S-sulfuration of Cys 247 was also detected after NaSH, or 
polysulfide treatments (m/z 781.89). 
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Figure 3.4.6-1 Michaelis-Menten kinetics of purified C156S mutant of GAPDH enzyme 
(KM = 0.23 ± 0.08 mM, Vmax = 49 ± 8 µM/min). The error bars represent standard error 
(n=3). Adapted from [254] with permission. 
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Figure 3.4.6-2 (A) Enzymatic activity of purified C156S GAPDH (1 µg/mL) as a 
function of increasing NaSH concentration. (B) Enzymatic activity of purified C156S 
GAPDH (1 µg/mL) as a function of increasing PS concentration. The error bars represent 
standard error (n=3). Adapted from [254] with permission. 
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Table 3.4.6-1 Cysteine-containing tryptic peptides sequenced by ESI-MS/MS analysis of 
purified C156S GAPDH enzyme; control, treated with sulfide (NaSH), treated with 
polysulfides (PS). Adapted from [254] with permission. 
Treatments Sequence Modification Cysteine Precursor 
ion m/z
a
 
IAM VPTANVSVVDLTCR -S-H 247 737.39 
VPTANVSVVDLTCR -S-CAM 247 765.90 
IISNASCTTNSLAPLAK -S-H 152 852.45 
IISNASCTTNSLAPLAK -S-CAM 152 880.96 
IAM 
NaSH 
 
VPTANVSVVDLTCR -S-H 247 737.39 
VPTANVSVVDLTCR -S-CAM 247 765.90 
VPTANVSVVDLTCR -S-S-CAM 247 781.89 
IISNASCTTNSLAPLAK -S-H 152 852.45 
IISNASCTTNSLAPLAK -S-CAM 152 880.96 
IISNASCTTNSLAPLAK -S-S-CAM 152 896.95 
IAM 
PS 
 
VPTANVSVVDLTCR -S-H 247 737.39 
VPTANVSVVDLTCR -S-CAM 247 765.90 
VPTANVSVVDLTCR -S-S-CAM 247 781.89 
IISNASCTTNSLAPLAK -S-H 152 852.45 
IISNASCTTNSLAPLAK -S-CAM 152 880.96 
IISNASCTTNSLAPLAK -S-S-CAM 152 896.95 
a 
All precursor ions reported are +2 ions unless otherwise indicated in () beside the m/z. 
Abbreviations:
 
CAM, carbamidomethyl; IAM, iodoacetamide; PS, polysulfide. 
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3.4.7 Additional MS/MS Spectra 
Individual MS/MS spectra have been included in Appendix A. Identical precursor ions 
sequenced in multiple samples are only shown once. 
 3.4.8 Molecular Dynamics Simulations of GAPDH 
GAPDH S-sulfuration was studied computationally using a molecular dynamics 
simulation to examine the effect of S-sulfuration of Cys 156 on the structure of GAPDH. 
Two important areas of the enzyme were examined; the NAD+ binding site and the 
catalytic site. Three important residues in the NAD+ binding were examined; Arg 13, Asp 
35, and Asn 316 [255]. After S-sulfuration of Cys 156, the residues changed position 
<0.5 Å, including the Cys 152 to Cys 156 distance (Figure 3.4.8-1). The Cys 152 to Asn 
316 distance did increase by 0.7 Å. From these results the NAD+ binding site did not 
change significantly after Cys 156 S-sulfuration. Critical catalytic residues Cys 152 and 
His 179, as well as residues Ser 151, Cys 152, Thr 153, Thr 211 responsible for inorganic 
phosphate binding (Pi site) were examined [256]. After S-sulfuration of Cys 156, the Cys 
152 to His 179 distance increased by 0.5 Å (Figure 3.4.8-2). Residues in the GAPDH Pi 
site Ser 151, Cys 152, and Thr 153 do not change significantly relative to each other 
(<0.5 Å) after S-sulfuration of Cys 156, with the exception of the distance from Thr 153 
to Thr 211, which does increase by 0.78 Å. The pKa of Cys 152 was studied 
computationally using the propKa algorithm. The pKa of Cys 152 was 5.81 in the wild-
type GAPDH enzyme, while the pKa of Cys 152 was 6.31 in the GAPDH enzyme S-
sulfurated at Cys 156. The pKa of the catalytic cysteine was observed across all time 
scales and was found to be 0.5 higher on average when Cys 156 was S-sulfurated. 
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Figure 3.4.8-1 Representative structure taken from Molecular Dynamics (MD) 
simulation of GAPDH showing residues from two NAD+ binding sites overlaid, gray 
carbons represent the structure with free (-SH) Cys 156, while brown carbons represent 
the structure with S-sulfurated (-SSH) Cys 156. Distances in Å were measured between 
critical NAD+ binding residues (Arg 13, Asp 35, Asn 316) as well as Cys 152 and Cys 
156. Only one protein backbone is shown. Reprinted from [254] with permission. 
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Figure 3.4.8-2 Representative structure taken from Molecular Dynamics (MD) 
simulation of GAPDH showing residues from two active sites overlaid, gray carbons 
represent the structure with free (-SH) Cys 156, while brown carbons represent the 
structure with S-sulfurated (-SSH) Cys 156. Distances in Å between critical catalytic 
residues Cys 152 and His 179 were measured. Distances between residues in the Pi site 
(Ser 151, Cys 152, Thr 153, Thr 211) were also measured. Only one protein backbone is 
shown. Reprinted from [254] with permission. 
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3.5 Discussion 
 3.5.1 S-Sulfuration of Vasopressin 
Vasopressin was used as a model peptide for the S-sulfuration of oxidized thiols. In our 
experiments vasopressin was S-sulfurated by NaSH and polysulfides, however high 
concentrations of NaSH or polysulfides were required to produce vasopressin S-
sulfuration (Figure 3.4.1-1). At least 1000 fold NaSH or polysulfide was required to 
detect vasopressin S-sulfuration by MALDI-MS. These results show that S-sulfuration of 
oxidized protein thiols is possible by NaSH and polysulfides. S-sulfuration at low 
concentration of sulfide, and protein thiol reduction at high concentration, as described by 
Francoleon et al. [162] was not detected with vasopressin.  
3.5.2 S-Sulfuration of Reduced GAPDH 
In our experiments with reduced GAPDH, it was found that NaSH had no significant 
effect on reduced GAPDH activity, even with 500 µM NaSH (Figure 3.4.2-2A). 50 µM 
NaSH also had no effect on the kinetic parameters of GAPDH (Figure 3.4.2-1). Since 
polysulfides have been postulated to be important H2S-derived signaling molecules, we 
tested the effect of polysulfides on GAPDH activity. It was found polysulfides 
significantly decreased the activity of GAPDH (Figure 3.4.2-2B). When analyzed by ESI-
MS/MS it was found active site Cys 152 was not S-sulfurated by either NaSH or 
polysulfides (Table 3.4.2-1). Cys 247 was S-sulfurated in the NaSH treated sample, while 
Cys 247 and Cys 156 were S-sulfurated after polysulfide treatment. Cys 156 S-sulfuration 
correlated with a decrease in enzymatic activity. These results indicate that polysulfides 
are a stronger S-sulfurating agent than NaSH. 
Since S-sulfuration of reduced GAPDH at Cys 247 was observed this raises the 
question of how NaSH can react with cysteine thiols, since both NaSH and cysteine thiols 
are in fully reduced states [161]. NaSH is only 60% pure and is contaminated with 
elemental sulfur; it is highly likely polysulfides are formed in solution when NaSH is 
dissolved. We therefore propose that NaSH mediated S-sulfuration of free cysteine occurs 
from NaSH-derived polysulfides. This idea is consistent with our results where 
polysulfides produce more S-sulfuration (both Cys 156 and Cys 247) than NaSH (only 
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Cys 247). It is however possible that S-sulfuration of Cys 156 is also occurring in the 
NaSH-treated sample, since the parent peptide (m/z 933) was detected in MS 
measurements, but was below intensity threshold to trigger MS/MS sequencing (data not 
shown). The stoichiometry of the modification may be too low to affect enzyme activity. 
3.5.3 S-Sulfuration of Glutathionylated GAPDH 
After oxidation of GAPDH with GSSG to form glutathionylated cysteines it was found 
NaSH and polysulfides had near equal ability to restore GAPDH activity as DTT (Figure 
3.4.3-1). Activity increased proportionally with the addition of NaSH or polysulfides 
from ~25% of control untreated enzyme to a maximum of ~70%. This represents ~3 fold 
increase in enzymatic activity from the GSSG-treated enzyme. We speculate that the fold 
increase in enzymatic activity may be increased if the initial oxidation of GSSG is 
stronger. It is unknown why 100% restoration of enzymatic activity with DTT was not 
observed. During treatments and buffer exchanges the control samples were subject to the 
same sample handling steps to minimize error. 
 Mass spectrometry analysis revealed glutathionylation of Cys 247 (Table 3.4.3-1) 
after GSSG treatment. After NaSH or polysulfide treatment glutathionylation of Cys 247 
was still detected, meaning NaSH and polysulfides did not reduce all protein-glutathione 
disulfides. Similarly to the reduced GAPDH results, NaSH treatment produced S-
sulfuration of Cys 247, while polysulfides S-sulfurated Cys 247 and Cys 156. When 
treated with NaSH or polysulfides, oxidized protein thiols therefore have the potential to 
be both reduced and S-sulfurated. A complex mixture of oxidized, reduced, and S-
sulfurated thiols is present (Table 3.4.3-1). The resultant enzymatic activity is therefore 
expected to be determined by the relative contribution of each modification. In addition, 
free unmodified thiols (-SH) were detected. These could be from incomplete labeling 
with iodoacetamide or de-glutathionylation of the enzyme after iodoacetamide treatment. 
3.5.4 H2O2-Oxidized GAPDH Activity 
After H2O2 treatment DTT was partially able to restore H2O2-oxidized GAPDH activity 
(Figure 3.4.4-1). NaSH was able to restore GAPDH activity to a much smaller extent 
than DTT. Polysulfides did not affect H2O2-oxidized GAPDH activity. Large reactivation 
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was not observed, likely due a mixture of sulfenic, sulfinic, and sulfonic acid derivatives 
being formed. Sulfinic and sulfonic acid derivatives are considered chemically 
irreversible, while sulfenic acids may be reduced by reducing agents [257]. The results 
suggest NaSH is a stronger reducing agent than polysulfides for sulfenic acids, although 
additional experiments would be required to prove this. H2O2 oxidized GAPDH was not 
studied using mass spectrometry. 
3.5.5 Reaction of NaSH or Polysulfides with S-Nitrosated GAPDH  
GSNO pre-treated GAPDH showed a biphasic response to increasing NaSH and 
polysulfide concentrations (Figure 3.4.5-1). Initially, activity decreased with increasing 
NaSH or polysulfide concentration until 50 µM, after which, activity increased with 
concentration. This may be due to S-nitrosothiols promoting S-sulfuration at low sulfide 
concentrations, and sulfide acting as a reducing agent at high concentrations. However, 
when analyzed by mass spectrometry no S-sulfuration was detected (Table 3.4.5-1). For 
mass spectrometry analysis 50 µM NaSH or polysulfides was used, which is the point of 
lowest activity, and presumably highest S-sulfuration. One possibility is that the 
carbamidomethyl disulfide was not stable under the extra sample handling steps. To the 
author’s knowledge this is the first time labeling with iodoacetamide and NEM has been 
used to try to simultaneously detect S-nitrosation and S-sulfuration. The method perhaps 
needs to be validated with a known S-sulfurated enzyme (eg. reduced GAPDH treated 
with polysulfides). The second possibility is that S-nitrosation does not promote S-
sulfuration, and instead an unexpected chemical species was formed. Work by Filipovic 
et al. identified the product of the reaction of H2S with GSNO as thionitrous acid 
(HSNO) and reduced glutathione (GSH) [135]. 
3.5.6 S-Sulfuration of Cys 152 in C156S GAPDH 
During all our experiments with the wild-type enzyme no S-sulfuration of Cys 152 was 
observed. In order to observe the effects of Cys 152 S-sulfuration, a C156S mutant was 
purified. After treatment with NaSH the C156S mutant showed a gradual decrease in 
enzymatic activity (Figure 3.4.6-2). After polysulfide treatment the C156S mutant 
showed a rapid decrease in enzymatic activity at low concentrations and a gradual 
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increase at high concentrations. The response was more drastic to NaSH and polysulfides 
than the wild-type enzyme. When analyzed by mass spectrometry Cys 152 was S-
sulfurated. These results correlate Cys 152 S-sulfuration with a decrease in enzymatic 
activity, contrary to previous literature results [141]. However, our results are in 
agreement with work by Valentine et al. from 1987 [258], where persulfides, generated 
through interaction of pyridoxal phosphate and cystine, inhibited GAPDH. 
 3.5.7 Role of GAPDH Cys 156 
In our experiments with the wild-type GAPDH enzyme it was observed Cys 156 was S-
sulfurated but Cys 152 was not. Results after GSNO treatment also indicate that Cys 156 
is more readily S-nitrosated than Cys 152. After mutating Cys 156 to a serine, Cys 152 
was S-sulfurated under our conditions. These experiments show Cys 156 is more reactive 
than Cys 152. We therefore propose a new role for Cys 156 where Cys 156 is a protective 
thiol for the adjacent catalytic Cys 152. This proposed function needs to be verified in 
vivo. Cys 156 is conserved and present in E. coli., B. stearothermophilus, lobster, rabbit, 
and human GAPDH [252], supporting our hypothesis. Cys 247 on the other hand is not 
conserved. If Cys 156 is more reactive than Cys 152, we can expect Cys 156 to have a 
lower pKa than Cys 152. This was not investigated in the present study, but is an 
interesting question that could be studied in the future. 
3.5.8 NaSH and Polysulfide S-Sulfuration 
In experiments with reduced and oxidized GAPDH, polysulfides produced S-sulfuration 
of Cys 156, while NaSH did not. In enzymatic assay experiments with reduced, GSNO-
oxidized, and C156S mutant of GAPDH, polysulfides produced stronger decreases in 
enzymatic activity than NaSH. The results show that polysulfides are a stronger S-
sulfurating agent than NaSH. Since NaSH was able to S-sulfurate reduced GAPDH at 
Cys 247, NaSH may be able to S-sulfurate thiols through NaSH-derived polysulfides. 
Based on these results, one can speculate that pure H2S will be an even weaker S-
sulfurating agent than NaSH, since NaSH is only ~60% pure once can expect it to form 
polysulfides more readily. Although it was not tested in the present study, Na2S-induced 
S-sulfuration could be used to test this theory. 
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 3.5.9 Effect of Enzyme Buffer on Treatments 
In this study all treatments of GAPDH were performed in 20 mM Tris buffer at pH 7.8. 
Treatment of the GAPDH enzyme in GAPDH assay buffer (20 mM Tris pH 7.8, 100 mM 
NaCl, 1 mM NAD+, 10 mM sodium pyrophosphate, 20 mM sodium arsenate, and 0.1 
mg/mL BSA) may produce undesired reactions with buffer components such as arsenate. 
Since GAPDH was not supplemented with the co-enzyme NAD+, we explored the 
possibility that NAD+ binding may change the structure of GAPDH, and in turn change 
the response to NaSH or polysulfides. In an experiment where GAPDH was in 20 mM 
Tris buffer at pH 7.8 supplemented with NAD+, treatment with NaSH produced the same 
results as the Tris buffer without NAD+ (Appendix A). 
 3.5.10 Computational Chemistry 
A molecular dynamics (MD) simulations was performed to examine the effect of Cys 156 
S-sulfuration on GAPDH structure. The NAD+ binding site was examined since the 
limiting step of GAPDH catalysis is NADH release [252]. It was found that the structure 
of the NAD+ binding site does not change significantly after Cys 156 S-sulfuration. In the 
GAPDH active site, the hydrogen bond between the thiolate anion of Cys 152 and 
protonated imidazole of His 179 increases by 0.5 Å upon Cys 156 S-sulfuration. This 
increase in the hydrogen bonding distance would disrupt the ability of His 179 to stabilize 
the Cys 152 thiolate negative charge. Consequently, the pKa of the Cys 152 thiolate will 
increase, reducing its nucleophilicity. MD simulations show the pKa of Cys 152 increased 
by 0.5, from 5.81 in the unmodified enzyme to 6.31 in the S-sulfurated enzyme. This may 
help explain the reduced enzymatic rate upon Cys 156 S-sulfuration. In the phosphate 
binding site (Pi site) Thr 211 shifts 0.78 Å away from Thr 153. This may also affect the 
effectiveness of the Pi site to stabilize charges from inorganic phosphate. The MD 
simulation was performed on a single crystal structure. Since GAPDH is a homotetramer 
one subunit was S-sulfurated and compared to the wild-type subunit within the same 
enzyme homotetramer. After the simulation was completed the two subunits were 
compared. It would be interesting to perform two separate simulations, where the same 
subunit is modified, and compare the results to see if they agree with the single 
simulation.  
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3.6 Conclusions 
In this chapter we investigated the reported S-sulfuration of GAPDH using a purified 
GAPDH enzyme. The effect of the initial redox state of the enzyme on S-sulfuration was 
examined. It was found that NaSH treatment did not significantly alter the enzymatic 
activity of reduced GAPDH. Treatment with polysulfides caused a decrease in GAPDH 
enzymatic activity. Treatment with NaSH caused S-sulfuration of Cys 247, while 
treatment with polysulfides caused S-sulfuration of Cys 156 and Cys 247. S-sulfuration of 
active site Cys 152 was not detected in the wild-type enzyme. Both NaSH and 
polysulfides were able to restore the activity of glutathionylated GAPDH with similar 
effectiveness as DTT. Similarly to the reduced enzyme, treatment of the glutathionylated 
enzyme with NaSH caused S-sulfuration of Cys 247, while treatment with polysulfides 
caused S-sulfuration of Cys 156 and Cys 247. Using a C156S mutant of GAPDH, NaSH 
and polysulfides were able to cause S-sulfuration of active site Cys 152, however a 
decrease in enzymatic activity was observed, and not an increase as previously reported. 
S-sulfuration of Cys 152 and Cys 156, both cause decreases in enzymatic activity. Based 
on our results, polysulfides are a stronger S-sulfurating agent than NaSH. S-sulfuration of 
reduced thiols by NaSH may be due to NaSH-derived polysulfides. We also propose a 
new role for GAPDH Cys 156, as a protective thiol for the catalytic residue Cys 152.  
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CHAPTER 4 
 
ENRICHMENT OF SULFUR-CONTAINING PEPTIDES BY GOLD 
NANOPARTICLES FOR MASS SPECTROMETRY ANALYSIS 
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4.1 Introduction 
Cysteines occur at a relative low frequency in proteins, however approximately 97% of 
human proteins contain at least one cysteine residue [259]. The relative amount of 
cysteine-containing proteins has been correlated with organism complexity. For example 
cysteines account for 0.5% of protein amino acids in archaebacterial, increasing to 2.26% 
in mammals. This suggests an important evolutionary role for cysteine residues, where 
the chemistry of cysteine residues allows for more complex protein functions. Cysteine 
residues serve a number of important roles in proteins. Cysteines are involved in 
maintaining protein structure by forming disulfide bonds and functional motifs, for 
example zinc fingers. Cysteine residues also function as redox switches, and are subject 
to a number of post-translational modifications [215, 257, 260-265]. Important cysteine 
modifications include disulfide formation, S-nitrosation, S-glutathionylation, sulfenic, 
sulfinic and sulfonic acid formation. Although once considered a mostly detrimental 
event in disease states and aging, macromolecule oxidation is now considered an 
important regulatory mechanism in healthy tissues [266]. Identification of modified 
cysteine residues and validation of their biological significance is important in 
elucidating the complex redox-dependent modifications that occur in the cell. 
 The most accurate method for identifying post-translational modification sites is 
mass spectrometry. Mass spectrometry allows unambiguous identification of protein 
modification sites, without the need to generate and test mutants of a protein. Although 
mass spectrometry is an extremely sensitive technique, the relative abundance of proteins 
of interest may be very low in comparison to background protein. Protein of interest may 
be present in detectable quantities, however may not appear in the MS spectra due to high 
background. This is especially an issue in methods like MALDI-MS, where usually there 
is no chromatography step to separate peptides from each other. In addition to having low 
abundance, modified proteins may also be in low stoichiometry compared to unmodified. 
This makes sample preparation and enrichment strategies important, in order to reduce 
sample complexity by removing abundant structural and housekeeping proteins, which 
aids in detection of low-abundance proteins of interest [265]. 
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 In recent decades there has been tremendous growth in the area of nanoparticle 
research, due to advances in synthesis and characterization methods. One of the most 
widely studied types of metal nanoparticles are gold nanoparticles (AuNPs).  Ease of 
synthesis, and useful properties such as surface plasmon resonance and inertness make 
them attractive for use in applications such as spectroscopy, sensing, imaging, and drug 
delivery [267-270]. Due to their high surface area, nanoparticles offer an attractive 
platform for mass spectrometric enrichment strategies of peptides. Gold can form strong 
bonds with soft ligands such as thiols, a property which is exploited in the stabilization 
and derivatization of AuNPs, as well as in the field of self-assembled monolayers [271]. 
Thiols also have the ability to displace weaker-binding ligands from Au, a property which 
is utilized in popular AuNP synthesis strategies [272]. Au-bound thiols can undergo thiol 
exchange with each other, the extent of thiol exchange depending on concentrations, and 
importantly, the chemical structure of the thiol ligands [273]. Much like ligand 
displacement and thiol exchange in preparation of nanoparticles and self-assembled 
monolayers, we tested the hypothesis that peptides containing thiols could displace 
weakly-bound citrate ligands, and be subsequently purified by thiol exchange using a 
small molecular weight thiol such as DTT. Unlike water-soluble PEG or carboxylate 
alkylthiol AuNPs, citrate capped AuNP provide low-affinity ligands with similar 
structure to peptides that could be displaced with thiol-containing peptides [274].  
Our group developed a AuNP-based method for identifying protein S-nitrosation 
sites, which relies on the natural affinity of thiols for gold [275]. In the original 
publication the method was tested with a single purified protein. Here we use a mixture 
of 5 purified proteins. Three recombinant proteins were used in the study: cystathionine 
gamma-lyase (CSE), protein disulfide isomerase (PDI), and dual specificity phosphatase 
12 (DUSP 12 or YVH1). Two proteins were commercially purchased: bovine serum 
albumin (BSA) and lysozyme. This generates a considerably more complex sample, 
however makes identification of individual peptides possible using post source decay 
(PSD) MALDI sequencing. PSD sequencing does not use a collision chamber to 
fragment peptides. As a result many peptides do not fragment well, preventing de-novo 
sequencing. 
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4.2 Materials 
 4.2.1 Reagents 
Gold (III) chloride trihydrate (520918), bovine serum albumin (A-9647), lysozyme (L-
7651), α-cyano-4-hydroxycinnamic acid (476870) were purchased from Sigma-Aldrich. 
DTT (100597) was purchased from MP Biomedicals. C18 Zip Tips® (ZTC18S096) were 
purchased from Millipore. Sequencing grade trypsin (V511A) was purchased from 
Promega. ZebaTM desalting columns (89882) were purchased from ThermoFisher. 
Acetonitrile and 0.1% trifluoroacetic acid solution were mass spectrometry grade 
reagents. 
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4.3 Methods 
4.3.1 AuNP Synthesis 
AuNPs were synthesized according to the protocol by Grabar et al. [276]. The synthesis 
was scaled down to produce 250 mL of AuNPs. A 500 mL round-bottom flask was 
cleaned with aqua regia (1:3 concentrated HNO3:HCl) and rinsed with Milli-Q water 
before use. Gold (III) chloride trihydrate (HAuCl4•3H2O) was dissolved in Milli-Q water 
to a concentration of 1 mM. 250 mL of this solution was refluxed with vigorous stirring 
to ~100 °C. When the temperature stabilized, 25 mL of a 38.8 mM solution of trisodium 
citrate dihydrate (Na3C5H5O7•2H2O) in Milli-Q water was very rapidly injected using a 
syringe. A rapid colour change from yellow, to clear, and to dark red was observed. 
Reflux and stirring was continued for 10 min after injection, the heat source was 
removed, and the solution was stirred for another 15 min. The resulting colloidal solution 
was cooled to room temperature and stored in a brown glass flask at 4 °C until usage. The 
UV-vis spectrum of the resulting AuNP solution showed a λmax of 520 nm. Long-term 
storage of AuNPs at 4 °C may be detrimental for AuNP stability, since precipitation was 
observed at a later date.  
4.3.2 Protein Purification and Digestion 
Recombinant human YVH1 was purified by the Vacratsis group (University of Windsor) 
according to the published protocol [277], and kindly donated for our experiments. 
Recombinant PDI and CSE were purified from E. coli containing the appropriate 
expression vector according to the detailed protocol by Faccenda et al. [185]. Bovine 
serum albumin and lysozyme were each dissolved in 50 mM Tris-HCl, 1 mM CaCl2 pH 
7.6. CSE, PDI, and YVH1 were each buffer-exchanged into 50 mM Tris-HCl, 1 mM 
CaCl2 using Zeba
TM Desalt Spin Columns. Each protein was trypsin-digested for 18 h at 
37 °C while shaking, using a trypsin:protein ratio of 1:40 by mass (protein concentration 
0.2 µg/µL). BSA, lysozyme, CSE, PDI, and hYVH1 were mixed in a 1:1:1:1:1 ratio after 
digestion.  
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4.3.3 Peptide Purification by AuNPs 
500 uL of AuNPs were centrifuged at 16,000 g for 10 min and 450 µL of the supernatant 
was removed to concentrate the AuNPs. 40 µg (0.2 µg/µL) of the unquenched tryptic 
protein digest was added to the AuNPs. The digest was incubated with AuNPs for 1 h at 
room temperature. The AuNPs were centrifuged at 16,000 g for 10 min. The supernatant 
was removed and the AuNPs were resuspended in 500 µL of 10 mM sodium phosphate 
buffer (pH 7.0) with sonication to redisperse aggregates. The AuNPs were centrifuged at 
16,000 g for 10 min and the supernatant was removed. Washing with 500 µL of 10 mM 
sodium phosphate buffer (pH 7.0) was repeated two more times. After the last wash 40 
µL of 50 mM DTT was added to the AuNP pellet. The AuNPs were redispersed with 
sonication, and incubated in DTT for 1 h. The AuNPs were centrifuged at 16,000 g for 15 
min and the supernatant was removed for analysis. 
4.3.4 Mass Spectrometry 
The DTT elution was acidified with 20 µL 0.1% trifluoroacetic acid and purified with 
Millipore C18 ZipTips®. 1 µL of sample was spotted with 1 µL of 10 mg/mL matrix 
solution (α-cyano-4-hydroxycinnamic acid in 60% acetonitrile, 0.1% trifluoroacetic acid) 
on a MALDI plate, and analyzed by an Applied Biosystems Voyager DE-Pro Mass 
Spectrometer. Linear mode was used to acquire fingerprint spectra. The fingerprint and 
PSD (post-source decay) spectra were manually compared to the masses predicted by 
UCSF Protein Prospector (http://prospector.ucsf.edu).  
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4.4 Results 
 4.4.1 Sulfur-Containing Peptide Enrichment by AuNPs 
In the control digest, before AuNP purification six sulfur-containing peptides are 
observed (Figure 4.4-1 and Table 4.4-1). Three of the peptides are thiols (cysteine 
containing). A high baseline signal is observed in the control sample indicating a 
complex mixture. After AuNP purification thirteen sulfur-containing peptides are 
observed, including seven cysteine-containing peptides (Figure 4.4-2 and Table 4.4-2). 
The baseline signal has considerably decreased (Figure 4.4-2) and sulfur-containing 
peptides constitute a much larger proportion of the detected peptides versus the control. 
Some non-sulfur peptides are still present after AuNP purification. 
4.4.2 Additional MALDI-MS PDS Spectra 
Individual MALDI-MS PSD spectra have been included in Appendix B. 
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Figure 4.4-1 MALDI-MS spectrum of a tryptic digest of a mixture of 5 proteins: BSA, 
CSE, lysozyme, PDI, and YVH1. Six sulfur-containing peptides were identified in the 
sample. 
 
Figure 4.4-2 MALDI-MS spectrum of a tryptic digest of a mixture of 5 proteins: BSA, 
CSE, lysozyme, PDI, and YVH1, subject to sulfur enrichment by AuNPs. Thirteen 
sulfur-containing peptides were identified in the sample. 
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Table 4.4-1 Sulfur-containing peptides identified by MALDI-MS in a tryptic digest of a 
mixture of 5 proteins; BSA, CSE, lysozyme, PDI, and YVH1. 
Peptide Sequence Observed 
Avg. m/z 
Predicted 
Avg. m/z 
Protein 
CVAFIGQAR 965.94 965.17 YVH1 
MNEGFEWQLK 1282.84 1282.47 YVH1 
GSHMASMTGGEEMGR 1537.17 1538.73 PDI 
LGSFNWYGEQCSCGR 1706.28 1707.89 YVH1 
IKPHLMSQELPEDWDKQPVK 2419.36 2419.82 PDI 
GSPEFMLEAPGPSDGCELSNPSASR 2536.16 2536.77 YVH1 
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Table 4.4-2 Sulfur-containing peptides identified by MALDI-MS after AuNP-based 
purification of a tryptic digest of a mixture of 5 proteins: BSA, CSE, lysozyme, PDI, and 
YVH1. 
Peptide Sequence Observed 
Avg. m/z 
Predicted 
Avg. m/z 
Protein 
CRRSLFR 937.96 938.15 YVH1 
CVAFIGQAR 966.36 965.17 YVH1 
MTPSSMLTTGR 1183.16 1182.41 YVH1 
MNEGFEWQLK 1283.31 1282.47 YVH1 
WWCNDGRTPGSR 1436.16 1435.57 Lysozyme 
GSHMASMTGGEEMGR 1537.41 1538.73 PDI 
IVSDGNGMNAWVAWR 1677.65 1676.91 Lysozyme 
LGSFNWYGEQCSCGR 1708.41 1707.89 YVH1 
KIVSDGNGMNAWVAWR 1805.44 1805.08 Lysozyme 
RPCFSALTPDETYVPK 1825.68 1825.11 BSA 
IKPHLMSQELPEDWDKQPVK 2419.85 2419.82 PDI 
GSPEFMLEAPGPSDGCELSNPSASR 2536.71 2536.77 YVH1 
YMNGHSDVVMGLVSVNCESLHNR 2563.19 2562.92 CSE 
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4.5 Discussion 
 4.5.1 Spectra Interpretation 
The proteins used in this study have various abundances of sulfur-containing residues, 
ranging from 12 sulfur-containing residues in lysozyme to 40 sulfur-containing residues 
in BSA, 35 of which are thiols (cysteines). MALDI-TOF-MS remains a qualitative 
technique where many factors such as abundance, ionization efficiency, and ion 
suppression due to sample composition affect which peptides are observed in the MS 
spectra. As a result only six sulfur-containing peptides are observed in the five protein 
mixture, which increases to thirteen sulfur-containing peptides after AuNP purification. 
The proportion of sulfur-containing peptides is greatly improved after AuNP purification 
as the majority of non-sulfur peptides are removed from the spectra. 
 4.5.2 Interaction of Peptides and AuNPs 
Free thiols can bind to Au through gold-thiolate bonding. Disulfides are generally broken 
upon binding to the Au surface, resulting in a gold-thiolate bond [278, 279]. Thioethers 
cannot form gold-thiolate bonds but are adsorbed intact on Au surfaces [279-281]. 
Although Au binds preferentially to thiols, AuNPs can be stabilized using citrate, and Au 
has some affinity for the carboxyl groups in citrate. Since peptides are large, complex, 
molecules, with multiple charges, other functional groups likely contribute to binding to 
AuNPs. The binding of peptides to Au is likely not as strong as for alkyl-thiols since 
alkyl thiols are further stabilized with hydrophobic interactions from alkyl chains, which 
are not present in peptides. Low binding affinity is beneficial for allowing disulfide 
exchange with small molecular weight thiols like DTT. However, the binding may not 
provide high enough affinity to purify only thiol-containing peptides. If strong Au-
peptide binding was occurring one might expect only cysteine-containing peptides 
(thiols) to be purified, and not methionines (thioethers). However, purification of 
thioethers may be useful for studies where alkylating agents like iodoacetamide and N-
ethylmaleimide are used, which generate a thioether linkage. 
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4.6 Conclusions 
AuNPs were used to purify sulfur-containing peptides from a mixed tryptic digest of 5 
purified proteins: BSA, CSE, lysozyme, PDI, and YVH1. Using MALDI-MS analysis six 
sulfur-containing peptides were identified before AuNP enrichment, and thirteen after 
AuNP enrichment. Importantly, the proportion of sulfur-containing peptides in the 
spectra increases after AuNP purification. Both cysteines and methionines are purified by 
AuNPs, however non-sulfur peptides are not fully removed. The results demonstrate 
AuNPs may be used for sample purification in mass spectrometric studies of sulfur-
containing proteins.  
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CHAPTER 5 
 
DEVELOPMENT OF NO-RELEASING MATERIALS FOR WOUND HEALING 
APPLICATIONS 
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5.1 Introduction 
NO is an important mediator of wound healing, and NO-releasing materials have the 
potential to be used as therapeutic agents to improve wound healing [206, 282], both in 
disease states and healthy tissues. In this chapter we aimed to develop NO-releasing 
wound dressings to improve cutaneous wound healing. Two different designs of wound 
dressings have been proposed. In the first design the chemistry of NO release is due to 
the denitrosation of small molecular weight S-nitrosothiols by gold nanoparticles 
(AuNPs). In the second design the NO release is due to the reduction of NO2
- ions to NO 
by copper. The proposed S-nitrosothiol based design is activated by a pressure-sensitive 
membrane. Upon breaking a pressure-sensitive membrane, mixing of the two solutions 
would occur, and initiate the reaction of S-nitrosothiols and metals, which would release 
NO at the wound site (Figure 5.1-1). It has been proposed AuNPs denitrosate S-
nitrosothiols by forming a gold-sulfur bond and releasing NO in the process (Eq. 5.1-1) 
[283, 284].  
 
The second design features a chitosan polymer doped with either CuNPs or copper ions. 
Cu(I) can reduce NO2
- to NO (Eq. 5.1-2) [285], and can also denitrosate S-nitrosothiols to 
generate NO (Eq. 5.1-3) [286, 287]. A large number of studies indicate that chitosan has 
inherent antimicrobial, and wound healing abilities [288]. In this design chitosan is not an 
inert compound for suspending copper, but is also expected to improve the wound 
healing process.  
  
  
Chitin is the second most abundant natural polymer after cellulose [289]. Chitin is 
a derivative of glucose (N-acetyl-β-D-glucosamine) synthesized by many organisms, and 
forms the exoskeleton of arthropods (eg. insects, crustaceans), as well as the cell walls of 
fungi and yeast. Treatment of purified chitin with NaOH causes deacetylation of chitin 
forming chitosan (D-glucosamine) (Figure 5.1-2). Different types of chitosan are 
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characterized by their degree of deacetylation (DD), distribution of acetyl groups on the 
main chain, and the molecular weight. The amine groups on chitosan allow chitosan to be 
soluble in acidic solutions, although the exact solubility properties depend strongly on 
how the chitosan was purified from chitin [289]. Due to the abundance of amine groups 
in chitosan, chitosan has an ability to chelate metal ions. For divalent ions chitosan shows 
the highest selectivity towards Cu2+, while for trivalent ions chitosan shows highest 
selectivity towards Eu3+ and Nd3+ [290]. Since chitosan is a cationic polymer it could be 
also used to absorb and remove anionic dyes from solution [291]. Numerous studies have 
used chitosan to remove metal ions, and dyes from waste water [291, 292].  
 Chitosan has numerous possible biomedical applications due to the fact it’s a 
biodegradable and non-toxic polymer with intrinsic wound-healing properties. Chitosan 
also has intrinsic antimicrobial and antifungal properties [293]. The antimicrobial 
properties of chitosan are related to its DD, and higher DD chitosan produces stronger 
antimicrobial effects [294]. Although the exact mechanism is not known, it has been 
theorized that the positive charge on chitosan destabilizes and permeates the cell 
membrane of gram-negative bacteria [288, 293]. In gram positive bacteria chitosan may 
chelate multivalent cations which stabilize the cell wall [293]. Chitosan has been shown 
to promote blood clot formation, and commercial chitosan-based wound dressings have 
been shown to be more effective at stopping hemorrhage than standard cotton gauze in 
animal studies [295]. At least one chitosan-containing bandage has been commercialized 
(HemCon®) and has been tested as a hemostatic by EMS services [296] and the US 
Army [297]. A study by Gopal et al. in 2014 tested a solution of copper nanoparticles and 
chitosan dissolved in 0.1% acetic acid in an animal model of wound healing [298]. The 
solution showed improved wound healing compared to chitosan without copper 
nanoparticles, and the control. However, the control was 0.1% acetic acid solution and no 
untreated control was shown. A study by Khan et al. showed acetic acid chitosan films 
caused skin irritation, while lactic acid chitosan films did not [299].  
 Studies show that copper has antimicrobial [300, 301], and wound healing 
properties [302-304]. Copper is biocidal, and far less likely to produce adverse skin 
reactions than silver. In recent years, the rise of antibiotic-resistant bacteria has led to 
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renewed interest in the antimicrobial properties of copper [300, 301]. The use of copper 
touch surfaces in hospitals may help the spread of bacteria. The wound healing effects of 
copper are less widely-studied. In 2008 Borkow et al. hypothesized that persistence of 
chronic wounds may be caused by low local levels of copper [303]. Copper is an essential 
trace element, and many cellular processes important in wound healing are copper-
dependent. Borkow et al. tested copper oxide impregnated wound dressing in diabetic 
mouse, and showed copper oxide dressings improved wound healing [302]. The 
mechanism of action was hypothesized to be generation of H2O2 and hydroxyl radicals 
through redox cycling between CuO and Cu2O. Analysis by real-time PCR and 
histochemistry showed numerous proangiogenic growth factors were upregulated with 
the use of copper oxide wound dressings. 
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Figure 5.1-1 Proposed design of an S-nitrosothiol based NO-releasing wound dressing. 
Upon breaking of the disruptable membrane S-nitrosothiol solution and Ag- or Au- 
composite material would come in contact. Reaction of Ag or Au with S-nitrosothiols 
will cause denitrosation of S-nitrosothiols and NO release through the gas permeable 
membrane. 
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Figure 5.1-2 (A) Chemical structure of chitin. (B) Chemical structure of chitosan. 
Treatment of chitin with NaOH causes partial deacetylation resulting in chitosan. 50% 
deacetylation is shown in this example. 
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5.2 Materials 
 5.2.1 Reagents 
Gold (III) chloride trihydrate (520918), Sephadex® G-75 (G-75-120), cellulose (C8002), 
tetraethyl orthosilicate (TEOS) (86578), triethyl phosphate (TEP) (538728), Ca(NO3)2 
(20-296-7), AgNO3 (209139), diethylenetriaminepentaacetic acid (DTPA) (D6518), 
hydrazine (225819), ethylene glycol (102466), NaNO2 (237213), lactic acid (252476), 
CuCl (212946), Minimum Essential Medium (MEM), reduced glutathione were 
purchased from Sigma-Aldrich. Polydimethylsiloxane (PDMS) Sylgard® 184 Silicone 
Elastomer Kit was purchased from Dow Corning. Chitosan (AZ-78-6101) was purchased 
from Dungeness Environmental Solutions. Ethylene glycol diglycidyl ether (EGDE) 
(01479-100) was purchased from Polysciences. Gibco® Fetal Bovine Serum was 
purchased ThermoFisher. 
 5.2.2 Materials 
Septa-sealed vials (Supelco 27533) were purchased from Sigma-Aldrich. 1 mL syringes 
(309659) were purchased from BD. Polystyrene columns (29920) were purchased from 
Fisher Scientific. 
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5.3 Methods 
 5.3.1 AuNP Synthesis 
AuNPs were synthesized according to the protocol by Grabar et al. [276]. The synthesis 
was scaled down to produce 250 mL of AuNPs. A 500 mL round-bottom flask was 
cleaned with aqua regia (1:3 concentrated HNO3:HCl) and rinsed with Milli-Q water 
before use. Gold (III) chloride trihydrate (HAuCl4•3H2O) (Sigma Aldrich) was dissolved 
in Milli-Q water to a concentration of 1 mM. 250 mL of this solution was refluxed with 
vigorous stirring to ~100 °C. When the temperature stabilized, 25 mL of a 38.8 mM 
solution of trisodium citrate dihydrate (Na3C5H5O7•2H2O) (Sigma Aldrich) in Milli-Q 
water was very rapidly injected using a syringe. A rapid colour change from yellow, to 
clear, and to dark red was observed. Reflux and stirring was continued for 10 min after 
injection, the heat source was removed, and the solution was stirred for another 15 min. 
The resulting colloidal solution was cooled to room temperature and stored in a brown 
glass flask at 4 °C until usage. The UV-VIS spectrum of the resulting AuNP solution 
showed a λmax of 520 nm. Long-term storage of AuNPs at 4 °C may be detrimental for 
AuNP stability, since precipitation was observed at a later date. 
5.3.2 AuNP-PDMS  
0.2 mL of PDMS mixture was cast directly in vials. A ratio of 0.04 curing agent to 
monomer base was used. This was previously determined by Adam Faccenda to be the 
optimum for AuNP synthesis on PDMS surfaces. PDMS was cured for 40 minutes at 70 
°C. The vials were cooled to room temperature. 0.5 mL of a solution containing 10 mM 
HAuCl4 and 5 mM citrate was added to each vial. The vial was placed on a shaker at 
room temperature for 3 h. The vial was removed and any gold flakes were pipetted off 
the surface before the solution was removed. The resulting AuNP-PDMS was washed 
with H2O three times. Control vials were not treated with the HAuCl4 and citrate solution.  
 5.3.3 AuNP-G75 Sephadex 
PBS was added to G-75 Sephadex to make a slurry. An equal volume of AuNPs was 
added to the slurry, and mixed. The slurry was poured into a chromatography column, 
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and washed with PBS to remove unbound AuNPs. 100 µL of the slurry was taken out of 
the column and added to each septa-sealed vial. Control G-75 did not contain AuNPs. 
 5.3.4 AuNP-Cellulose 
1 g of α-cellulose was added to 40 mL of AuNPs. The mixture was placed on a nutating 
mixer. Excess AuNPs were removed as in the AuNP-G75 Sephadex protocol. 150 µL of 
the cellulose was added to each septa-sealed vial. 
 5.3.5 AuNP-Gauze 
A ~1 x 1 inch piece of gauze was placed in a petri dish. AuNPs were added, and the 
gauze was soaked overnight. The excess AuNPs were removed, and the AuNP-gauze was 
washed with H2O until no more AuNPs eluted from the gauze into the H2O (no red 
colour). The gauze was dried at ~50 °C. The gauze was compared by weight to a piece of 
control gauze. Pieces with approximately equal weight (~0.5 x 1 cm for AuNP and ~0.5 x 
1.5 cm for control) were cut and placed inside septa-sealed vials. 
 5.3.6 AuNP-Glass Synthesis 
AuNP doped glass was synthesized according to the sol-gel protocol published by 
Lusvardi et al. [305]. 3.542 g of Ca(NO3)2•4H2O and 0.788 g of HAuCl4•3H2O was 
dissolved in 12.96 mL of HCl (0.0091 M). 17.84 mL TEOS and 1.71 mL of TEP were 
added to 40 mL of ethanol. The Ca/Au solution was added to the TEOS/TEP solution and 
stirred well. The stirred solution was transferred to an airtight Teflon container and kept 
at room temperature for 24 h. The gel was transferred to an open crucible and heated for 
3 h at 600 °C. The control glass was prepared the same way except without the addition 
of HAuCl4•3H2O. 5 mg of AuNP-glass or control glass was placed in each septa-sealed 
vial for NO measurements. 
 5.3.7 Ag2S-Paper 
Filter paper was soaked twice in a methanol solution saturated with AgNO3. Filter paper 
was then rinsed in methanol solution three times, and air dried at room temperature. 10 
mM Na2S solution was added to the filter paper to form Ag2S. The filter paper was rinsed 
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in H2O solution three times, and air dried at room temperature. 9 mg of Ag2S-paper or 
control paper was used per vial for NO measurements. 
5.3.8 NO Measurements from AuNP and Ag Composites 
Vials containing the AuNP-composite and controls were sealed and degassed with argon 
for 7 minutes each. Sievers Nitric Oxide Analyzer (NOA 280i) was set up using the 
standard NO2
- measurement mode and standardized with NO2
- according to manufacturer 
protocol. GSNO was dissolved in 100 µM DTPA. 200 µL of GSNO was added to a 
degassed vial, the vial was incubated 10 minutes, and 1 mL of the headspace was injected 
into the reaction chamber. Separate syringes were used for GSNO and headspace 
injections. When gas from the vial headspace was injected into the NOA reaction 
chamber, it was injected into the reaction chamber headspace, and the syringe needle did 
not touch the solution inside. 
Each vial was timed exactly 10 minutes between injection of GSNO into vials and 
measurement of vial headspace. The addition of GSNO to individual vials was done in 2 
min intervals, and the subsequent injection of NO into the NOA was done in 2 min 
intervals (exactly 10 minutes later). By the 5th injection of GSNO, the injections of 
GSNO and NO will start overlapping. For simplicity and more accurate timing, the 
incubations and measurements were done in sets of 4 or 5 samples, so the injections of 
NO and GSNO did not overlap.  
5.3.9 CuNP Synthesis 
CuNPs were synthesized according to protocol by Zhu et al. [306]. 20 mL of N2H4 and 
NaOH in ethylene glycol was added to 20 mL of 0.1 M CuSO4 in ethylene glycol while 
stirring. The molar ratio of N2H4 to CuSO4 was 1.5, while the molar ratio of NaOH to 
CuSO4 was 0.05. The solution was irradiated in a household microwave oven and cycled 
18 s on, 12 s off, for 3 min. Nanoparticles were isolated by centrifugation and washed 
with anhydrous ethanol. 
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5.3.10 Chitosan and CuNP-Chitosan Film Preparation 
To prepare chitosan films, 0.2 g of chitosan was added to 9.6 mL H2O while stirring. 
Stirring was continued for 5 minutes. For CuNP-chitosan 10 mg of solid CuNPs were 
added. Stirring was continued for 5 minutes. 200 µL of acetic acid or lactic acid was 
added to the chitosan dropwise while stirring. Stirring was continued for 1 h. The CuNPs 
may slowly disperse and dissolve, however the process will not occur to completion. 
Chitosan was poured into weighing boats and dried for at least 48 h. Drying time will 
vary depending on temperature and humidity. Control chitosan and CuNP-chitosan, used 
for NO release experiments examining the effect of the addition of thiol to the films, was 
prepared using this method. Later an improved method was used (vide infra). The 
amounts may be scaled up depending on how much chitosan one wants to make. 0.2 g of 
chitosan in ~10 mL results in a 2% chitosan mixture. The volume added to weighting 
boats may be changed to control film thickness. 
 5.3.11 Cu-Chitosan Film Preparation, Glucose-Chitosan Film Preparation, and 
Improved CuNP-Chitosan Film Preparation 
An improved protocol was used to prepare CuNP-chitosan films in order to reduce time 
and improve CuNP dispersion. To prepare chitosan films, 0.2 g of chitosan was added to 
9.6 mL of H2O while stirring. Stirring was continued for 5 minutes. The solution was 
now transferred from a beaker to a falcon tube. 10 mg of solid CuNPs was added to the 
falcon tube, and the falcon tube was sonicated in a water bath sonicator to disperse the 
CuNPs. Afterwards, the solution was poured back into the same beaker, and stirring was 
continued. 200 µL of lactic acid was added to the chitosan dropwise while stirring. 
Stirring was continued for 5 minutes. 10 mL of 0.33 M glucose solution was now added, 
and stirred for 5 minutes. 5 mL of the resulting mixture was poured into each weighing 
boat, and dried for at least 48 h. 
 The amount of copper salt to be added to chitosan was calculated to be equivalent 
in mol Cu to 10 mg of CuNPs. For CuCl it was 0.0156 g, for Cu2O it was 0.0112 g, etc. 
To prepare chitosan, 0.2 g of chitosan was added to 9.6 mL of H2O while stirring. Stirring 
was continued for 5 minutes. Cu was added to the solution and stirring was continued for 
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5 min. 200 µL of lactic acid was added to the chitosan dropwise while stirring. Stirring 
was continued for 5 minutes. 10 mL of 0.33 M glucose solution was now added, and 
stirred for 5 minutes. 5 mL of the resulting mixture was poured into each weighing boat. 
When comparing chitosan with or without glucose, 10 mL of H2O was added instead of 
0.33 M glucose to keep the % of chitosan the same. Using this protocol the resulting 
chitosan concentration in the slurry was 1%, although the concentration can be easily 
adjusted if so desired. 6 mL of the resulting mixture was poured into each weighing boat, 
and dried for at least 48 h. 
 5.3.12 Cross-linked Chitosan Film Preparation 
Chitosan films were cross-linked by placing them in 1% EGDE solution in methanol on a 
shaker for 18 h. Films were washed with methanol to remove excess EGDE, and air 
dried. 
5.3.13 Solution Concentrations for NO Measurements of Chitosan and CuNP-
Chitosan, With, and Without GSH 
In the first experiment, 7 mg of chitosan, or CuNP-chitosan was placed in septa-sealed 
vials and degassed with argon for 5 minutes. 100 µL of 10 mM sodium phosphate buffer 
pH 7.0 and 100 µL of 100 µM NO2
- was injected into vials during measurements. 100 µL 
of GSH in 10 mM sodium phosphate buffer pH 7.0 was used for testing CuNP-chitosan 
in the presence of thiol, instead of buffer alone Time between injection of NO2
- and NO 
measurement was 10 minutes. 
 In the second experiment the amount of CuNP-chitosan was reduced to 2.5 mg. 
100 µL of 10 mM sodium phosphate buffer pH 7.0 and 100 µL of 50 µM NO2
- was 
injected into vials during measurements. 100 µL of 200 µM GSH in 10 mM sodium 
phosphate buffer pH 7.0 was used for the CuNP-chitosan in testing presence of thiol, 
instead of buffer alone. 
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5.3.14 Solution Concentrations for NO Measurements in the Comparison of 
Different Sources of Cu in Cu-Glucose-Chitosan 
0.5 x 0.5 cm chitosan squares were cut, placed in septa-sealed vials, and degassed with 
argon for 5 minutes. 100 µL of minimum essential media (MEM) supplemented with 
fetal bovine serum (FBS) and 100 µL 50 µM NO2
- was injected into the vials. Time 
between injection of NO2
- and NO measurement was 15 minutes. 
 5.3.15 Solution Concentrations for NO Measurements Determining the Effect 
of Glucose on Cu-Chitosan 
0.6 x 0.6 cm chitosan squares were cut, placed in septa-sealed vials, and degassed with 
argon for 5 minutes. 200 µL of 10 µM NO2
- in PBS was injected into vials. Time between 
injection of NO2
- and NO measurement was 15 minutes. 
 5.3.16 Solution Concentrations for NO Measurements of Cross-linked Chitosan 
and Cu-Chitosan 
0.5 x 0.5 cm chitosan squares were cut, placed in septa-sealed vials, and degassed with 
argon for 5 minutes. 200 µL of NO2
- in PBS and 100 µL of 2 g/L glucose in PBS was 
injected into vials. Time between injection of NO2
- and NO measurement was 15 
minutes. 
 5.3.17 NO Measurements from Chitosan and Cu-Chitosan Films 
Vials containing the Cu-chitosan and control chitosan were sealed and degassed with 
argon for 5 minutes each. Sievers Nitric Oxide Analyzer (NOA 280i) was set up using the 
standard NO2
- measurement mode and standardized with NO2
- according to manufacturer 
protocol. NO2
- in PBS was injected into the degassed vials, and vials were incubated 10 
minutes or 15 minutes depending on the experiment. 1 mL of the headspace was injected 
into the reaction chamber.  
Separate syringes were used for NO2
- and headspace injections. When aspirating 
the gas from the vial headspace one must be extremely careful not to touch the NO2
- 
solution inside. If the syringe comes in contact with NO2
-, the NO2
- will be converted to 
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NO in the NOA reaction chamber and give a false signal. When gas from the vial 
headspace was injected into the NOA reaction chamber, it was injected into the reaction 
chamber headspace, and the syringe needle did not touch the solution inside. Even when 
following this protocol previous contact with NO2
- may produce a false signal.  
Each vial was timed exactly 10 minutes between injection of NO2
- into vials and 
measurement of vial headspace. The addition of NO2
- to individual vials was done in 2 
min intervals, and the subsequent injection of NO into the NOA was done in 2 min 
intervals (exactly 10 minutes later). By the 5th injection of NO2
-, the injections of NO2
- 
and NO will start overlapping. For simplicity and more accurate timing, the incubations 
and measurements were done in sets of 4 or 5 samples, so the injections of NO2
- and NO 
did not overlap. When following the protocol with 15 minutes between injections sets of 
6 samples were used.  
Different types of samples were measured first, and subsequently replicates were 
measured. For example samples were injected in the order: control, copper, control, 
copper, control, copper, and not control, control, control, copper, copper, copper. This 
was done in case contamination of the syringe needle occurred, it would be easier to spot, 
and less likely to be mistaken for genuine NO release.  
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5.4 Results 
 5.4.1 NO Release from GSNO by Au and Ag Composites 
All the AuNP and Ag composites tested (AuNP-PDMS, AuNP-G75, AuNP-Cellulose, 
AuNP-Gauze, AuNP-Glass, Ag2S-Paper) were able to denitrosate S-nitrosothiols, 
producing gaseous NO (Figures 5.4.1-1 to 5.4.1-6). These results support the previously-
described denitrosation mechanism of S-nitrosothiols by AuNPs [283]. It is likely Ag can 
denitrosate S-nitrosothiols using a similar mechanism as Cu or Au. All the materials 
tested also displayed at least some de-nitrosation without any Au or Ag present. This is 
most likely due to metal ion contamination. However, the presence of AuNPs or Ag does 
provide significant increase in released NO. 
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Figure 5.4.1-1 NO release from GSNO by AuNP-PDMS compared to control PDMS. 1 
mL of headspace gas was measured 10 min after the addition of GSNO to a septa-sealed 
vial. 
 
 
Figure 5.4.1-2 NO release from GSNO by AuNP-G75 Sephadex compared to control 
G75 Sephadex. 1 mL of headspace gas was measured 10 min after the addition of GSNO 
to a septa-sealed vial. 
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Figure 5.4.1-3 NO release from GSNO by AuNP-cellulose compared to control 
cellulose. 1 mL of headspace gas was measured 10 min after the addition of GSNO to a 
septa-sealed vial. 
 
 
Figure 5.4.1-4 NO release from GSNO by AuNP-gauze compared to control gauze. 1 mL 
of headspace gas was measured 10 min after the addition of GSNO to a septa-sealed vial. 
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Figure 5.4.1-5 NO release from GSNO by AuNP-glass compared to control glass. 1 mL 
of headspace gas was measured 10 min after the addition of GSNO to a septa-sealed vial. 
 
 
Figure 5.4.1-6 NO release from GSNO by Ag2S-paper compared to control paper. 1 mL 
of headspace gas was measured 10 min after the addition of GSNO to a septa-sealed vial. 
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5.4.2 NO Release from NO2
-
 by Cu-Chitosan 
Chitosan embedded with CuNPs was able to generate NO from NO2
- (Figure 5.4.2-1). 
Copper is expected to be oxidized in this reaction from Cu(I) to Cu(II). GSH was added 
to the chitosan to test whether it could reduce Cu(II) back to Cu(I). In an experiment with 
10 mg chitosan there was no significant difference between copper and copper with GSH 
(Figure 5.4.2-1). When the amount of chitosan was reduced to 2.5 mg the addition of 
GSH did increase NO release (Figure 5.4.2-2), although the total NO released was much 
lower. 
Different sources of copper were tested to determine whether they can replace 
microwave synthesized CuNPs. In this experiment, glucose was added to the chitosan 
mixture before casting in order to attempt to improve the physical properties of the films. 
Minimum Essential Medium (MEM) supplemented with fetal bovine serum (FBS) was 
added to chitosan during NO release experiments to test whether cell culture media 
would interfere with potential cell culture experiments. It was found different copper 
sources (CuNP, CuSO4, CuCl, Cu2O) can facilitate release of NO from NO2
- in chitosan 
(Figure 5.4.2-3). This is likely due to the chitosan being supplemented with glucose. 
When using a CuCl as a source of copper, it was determined the addition of glucose to 
the chitosan before casting a film was required for NO release (Figure 5.4.2-4).  
Chemical cross-linking was used to try to improve the physical properties of the 
chitosan films and prevent cracking of the film after drying. It was found cross-linking 
prevented NO release by the Cu-chitosan films (Figure 5.4.2-5). In this experiment 
glucose was added to chitosan films alongside NO2
- during NO measurements. 
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Figure 5.4.2-1 NO release from NO2
- by 10 mg CuNP-chitosan with and without reduced 
glutathione (GSH). 1 mL of headspace gas was measured 10 min after 100 µL of pH 7.0 
10 mM PO4
3- buffer (with or without GSH) and 100 µL of 100 µM NO2
- was injected into 
a septa-sealed vial. Error bars represent standard error (n=3). 
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Figure 5.4.2-2 NO release from NO2
- by 2.5 mg CuNP-chitosan with and without 
reduced glutathione (GSH). 1 mL of headspace gas was measured 10 min after 100 µL of 
pH 7.0 10 mM PO4
3- buffer (with or without GSH) and 100 µL of 50 µM NO2
- was 
injected into a septa-sealed vial. Error bars represent standard error (n=3). 
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Figure 5.4.2-3 NO release from NO2
- by Cu-glucose-chitosan prepared using different 
sources of copper in the presence of minimum essential media (MEM) supplemented 
with fetal bovine serum (FBS). 1 mL of headspace gas was measured 15 min after 100 µL 
of MEM and 100 µL 50 µM NO2
- was injected into a septa-sealed vial. Error bars 
represent standard error (n=3). 
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Figure 5.4.2-4 Effect of glucose and CuCl on NO release from NO2
- by chitosan. CuCl 
and glucose were incorporated into chitosan films. 1 mL of headspace gas was measured 
15 min after 200 µL of 10 µM NO2
- in PBS was injected into a septa-sealed vial. Error 
bars represent standard error (n=3). 
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Figure 5.4.2-5 Effect of EGDE cross-linking of chitosan on NO release from NO2
-. 1 mL 
of headspace gas was measured 15 min after 200 µL of NO2
- in PBS and 100 µL of 2 g/L 
glucose in PBS was injected into a septa-sealed vial. Error bars represent standard error 
(n=3). 
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5.5 Discussion 
 5.5.1 NO Release from GSNO by AuNP and Ag Composites 
All of our AuNP and Ag composites tested were able to denitrosate S-nitrosothiols, and 
produce NO since they contain either Au or Ag. The presence of AuNPs or Ag does 
increase the NO release versus the control materials. The control materials did facilitate 
some NO release, which is likely due to trace metal contamination. PDMS uses a 
proprietary metal catalyst to cure the PMDS polymer, which can likely denitrosate S-
nitrosothiols. Other materials used are likely contaminated with trace metals. It is also 
possible the vials used were contaminated with trace metals. The relative NO release 
cannot be reliably compared, since the amount of Au or Ag in each material has not been 
quantified.  
 5.5.2 Proposed SNO-Based NO-Releasing Wound Dressing 
The proposed design of the wound dressing uses S-nitrosothiols as a source of NO. While 
the chemistry of S-nitrosothiols is convenient, this is problematic for storage of the 
wound dressing, as S-nitrosothiols are not stable at high temperatures. During use of the 
proposed wound dressing, the ambient temperatures could also affect NO release. S-
nitrosothiols are also unstable when exposed to light, and the external packaging would 
require the S-nitrosothiols to be protected from light. The proposed design uses gold to 
denitrosate S-nitrosothiols. Copper or silver could replace gold, which is an expensive 
material. The kinetics of NO release may be changed by changing the amount of metal in 
the composites. Although the kinetics of NO release may be prolonged, it is unknown if 
they could be prolonged for the extended periods of time that are required for wound 
healing.  
The design of the wound dressing itself introduces packaging challenges. The 
dressing design requires NO to diffuse through a gas-permeable membrane, and then 
through a traditional wound dressing, such as cotton gauze, to reach the site. The amount 
of NO actually released at the wound site would also have to be tested if a prototype was 
constructed. Furthermore, effective bandages allow gas-exchange at the wound site [307]. 
This could be a challenge due to the proposed design. The multi-layered design might not 
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effectively facilitate gas-exchange at the wound site. To facilitate gas exchange, a 
permeable membrane could be incorporated on both sides of the wound dressing, the side 
facing the wound and the side facing away. This would facilitate more gas exchange but 
also cause NO loss to the external environment.  
 5.5.3 NO Release from NO2
-
 by Cu-Chitosan Films 
The Cu-chitosan films were able to release NO from NO2
-, which is a salt, and more 
stable than S-nitrosothiols. During our initial experiments, CuNPs were used as the 
source of copper. CuNPs were synthesized by microwave synthesis [306] and added to 
the chitosan films. The CuNPs used are uncapped, meaning they have no capping agent 
like citrate in classic AuNPs. The copper in the CuNPs is in the Cu(0) oxidation state 
after synthesis. After the addition of acetic acid or lactic acid to CuNP-chitosan solution, 
the solution turns green indicating oxidation of the copper. The CuNPs do not fully 
dissolve, and when cast into a film do not disperse evenly, resulting in an uneven 
distribution of CuNPs in the film. Sonication improves this only to a certain extent. 
Since the copper partially oxidizes during casting of the films, it was tested 
whether the addition of thiols can increase the NO release by reducing Cu(II) to Cu(I). At 
high amounts of chitosan (10 mg) the addition of GSH did not significantly increase the 
amount of NO release (Figure 5.4.2-1). However, at lower amounts of chitosan (2.5 mg), 
the amount of reduced copper in the film becomes limiting and the addition of GSH does 
increase NO release (Figure 5.4.2-2). When glucose is cast with chitosan, other sources 
of copper can be used to generate NO from NO2
- (Figure 5.4.2-3). Glucose is a reducing 
sugar and can reduce Cu(II) to Cu(I), however it was incorporated into the film rather 
than added with NO2
-. The reduction of Cu(II) by glucose is the basis of Benedict's 
reagent, a reagent used in a colourimetric test for reducing sugars. When using copper 
salts like CuCl, copper was oxidized from Cu(I) to Cu(II) when incorporated into 
chitosan films, and glucose was required for NO release (Figure 5.4.2-4).  
 5.5.4 Physical Properties of Cu-Chitosan Films 
It was tested whether lactic acid can replace acetic acid for making chitosan films. Lactic 
acid is expected to be more biocompatible than acetic acid [299]. During mixing of a 
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chitosan solution, the acid is used to protonate the amino groups on chitosan and increase 
the solubility of chitosan in solution before casting of the film. The specific acid used for 
mixing the chitosan slurry is therefore interchangeable. When performing NO release 
experiments it is important that NO2
- is added to chitosan in a buffered solution, since 
residual acid can reduce NO2
- to NO. After casting of the chitosan slurry, the water 
evaporates to form a chitosan film. Prolonged evaporation results in a film that is 
extremely brittle. The addition of glucose allows the film to be soft for a longer period of 
time; however the film will eventually become brittle with prolonged drying. The 
browning reaction of glucose is also observed when drying the chitosan films. When 
placed in water the chitosan films swell and break apart. Chemical cross-linking was 
therefore used to try to improve the physical properties of the films, and prevent the films 
from breaking apart. Ethylene glycol diglycidyl ether (EGDE) was used as the cross-
linker, however cross-linking prevented NO release from chitosan films (Figure 5.4.2-5). 
Chemical cross-linking may also alter the chemical and biological properties of chitosan 
in an undesired way. 
 5.5.5 Proposed Design of Chitosan-Based NO-Releasing Wound Dressing 
The proposed NO releasing chitosan-based bandage combines therapeutic effects from 
chitosan, copper, and NO release. In this design the chitosan can be in contact with the 
wound, and does not require complex packaging unlike our previous AuNP and Ag based 
design. The use of chitosan also allows for gas exchange at the wound site. The use of 
copper allows two pathways for NO release, the reduction of NO2
- to NO, and the de-
nitrosation of S-nitrosothiols. The copper may be able to react with native NO2
- and S-
nitrosothiols to produce NO. Additional NO2
- may also be applied to the wound dressing, 
perhaps between the chitosan film, and an adhesive backing. Since the use of copper salts 
required the incorporation of glucose into the chitosan films, CuNPs may be the best 
copper source. Incorporating large amount of glucose, to reduce Cu(II), would likely be 
detrimental to wound healing. However, thiols and glucose present in biological fluids 
may provide a pathway for the regeneration of Cu(I) from Cu(II). 
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5.5.6 Future Directions 
In this work we studied the release of NO from copper-chitosan films in an endpoint 
manner. The next step is to study the kinetics of NO release, and determine how much 
NO the copper-chitosan films release over time. This would also help optimize the 
chemical composition of the films. Ultimately, to test the efficacy of the proposed wound 
healing dressings animal studies are required.  
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5.6 Conclusions 
In this chapter we sought to develop NO-releasing wound dressings that may be used to 
improve wound healing. The first wound dressing design is based on the denitrosation of 
S-nitrosothiols by gold or silver composites. The chemistry of S-nitrosothiols is 
convenient; however this design produces packaging challenges. The second design uses 
chitosan embedded with copper, which can reduce NO2
- to NO, as well as denitrosate S-
nitrosothiols. The use of chitosan and NO2
- eliminates the packaging challenges present in 
the first design. Our experiments show chitosan films embedded with copper are effective 
at reducing NO2
- to NO. Although our therapeutic agent is NO, numerous studies show 
that the use of chitosan or copper alone can improve wound healing in animal models. 
NO-releasing copper-chitosan may be used as a wound dressing to improve wound 
healing.  
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CHAPTER 6 
 
GENERAL DISCUSSION 
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6.1 Discussion and Perspectives 
The discovery of NO as a gasotransmitter in the late 1980’s has resulted not only in 
discovery of an important biological pathway, but the establishment of a whole new field 
of biological signaling. One of the major recent discoveries in the field of gaseous 
signaling is H2S signaling. Many similarities between NO and H2S exist: biological 
effects in the cardiovascular and nervous systems, interaction with biomolecules through 
cysteine residues and heme iron, complex chemistry due to oxidation by O2, and potential 
challenges when performing in vivo measurements. The study of gasotransmitters, like 
NO and H2S, requires a strong understanding of their underlying chemistry. The over-
estimation of H2S concentrations in biological samples highlights this issue. It also 
highlights the need for detailed understanding of analytical techniques used to detect H2S, 
and the need for improved H2S detection methods. Driven by the need for accurate and 
specific methods for detecting H2S, in Chapter 2 we developed a simple and specific 
assay for H2S gas. This assay requires no specialized equipment, and provides researchers 
an additional tool for studying H2S.  
Similarly to S-nitrosation by NO, H2S can modify cysteine residues by S-
sulfuration, affecting protein functions. In Chapter 3 we investigated the reported S-
sulfuration of the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). Our work on GAPDH S-sulfuration provides more insights into how H2S may 
modify GAPDH cysteine residues, and in-turn affect GAPDH enzymatic activity. 
Although our work was performed in vitro, it provides researchers clues about what could 
be potentially occurring in vivo. We also demonstrate the importance of the initial 
cysteine redox state of an enzyme, which will affect the response to gasotransmitters like 
NO and H2S, highlighting the importance of basic biochemistry in studying 
gasotransmitters. 
 Mass spectrometry is an extremely powerful and versatile tool for studying 
protein post-translational modifications, including modifications induced by 
gasotransmitters. In Chapter 4 we used the natural affinity of thiols and thioethers 
towards gold nanoparticles in order to purify sulfur-containing tryptic peptides for mass 
spectrometric analysis. Since cysteine residues are common targets of gasotransmitters 
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NO and H2S, this technique could be used for studying post-translational modifications of 
proteins induced by gasotransmitters. 
 Gasotransmitters like NO and H2S may also be used as therapeutic agents to treat 
disease. For example, nitroglycerin is used to treat angina pectoris, and its activity is due 
to the release of NO. Application of exogenous NO can improve cutaneous wound 
healing, and there is a possible therapeutic application of NO for treatment of chronic and 
persistent wounds. In Chapter 5 we developed NO-releasing materials that could be used 
as wound dressings to improve wound healing. Chitosan is a natural, biocompatible, and 
biodegradable polymer, which has been previously used as a wound dressing. By 
incorporating copper into chitosan films, chitosan films can generate NO from inorganic 
nitrite, and S-nitrosothiols. Although further studies are required, copper-chitosan films 
could be potentially used as NO-releasing wound dressing. 
 Our understanding of H2S signaling is a lot less complete than NO signaling. 
While NO is well-established to be a major determinant of vascular tone, H2S signaling 
could even be described as controversial. Although H2S and NO are similar, some unique 
challenges exist when studying H2S. The lack of specific enzyme inhibitors, as well as 
detection methods has been a major challenge in H2S research. H2S-producing enzymes, 
CBS, CSE, CAT, and 3-MST catalyze many different reactions in addition to H2S 
generation. It is difficult, but very important, to separate these functions from H2S-related 
effects. H2S can oxidize to numerous different sulfur species, and react with other redox 
signaling molecules, including NO. Determining which reactions occur physiologically 
will aid our understanding of H2S, and even NO biochemistry. Going forward, the 
development of improved methods to study H2S, and furthering our knowledge of H2S 
chemistry would greatly improve our understanding of H2S signaling. When drawing 
biological conclusions it is paramount to appreciate the chemistry of gasotransmitters, the 
chemical tools used to study gasotransmitters, and consider the big picture. 
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Appendix A 
 
Figure A-1 MALDI-MS spectra of vasopressin treated with 1,000 fold (1 mM) NaSH 
and labeled with iodoacetamide. m/z 1084 represents unmodified vasopressin, m/z 1117 
represents unlabeled singly S-sulfurated vasopressin, m/z 1175 represents singly S-
sulfurated and iodoacetamide labeled vasopressin, m/z 1232 represents singly S-
sulfurated and doubly iodoacetamide labeled vasopressin, m/z 1264 represents doubly S-
sulfurated and iodoacetamide labeled vasopressin. 
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Figure A-2 GAPDH protein purification gel. Lane 1: protein ladder, lane 2: purified 
GAPDH, lane 3: E. coli crude lysate. Image was taken using a desktop scanner. 
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Figure A-3 C156S GAPDH protein purification gel. Lane 1: protein ladder, lane 2: crude 
lysate, lane 3: column flow-through, lane 4: wash #1, lane 5: wash #2, lane 6: purified 
GAPDH. Image was taken using a commercial gel imager. 
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Figure A-4 Example plot of GAPDH enzyme activity. Conversion of NAD+ to NADH 
was measured at 340 nm. The initial rate up to 42 s was used for calculations.  
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Figure A-5 GAPDH enzyme inactivation by oxidized glutathione (GSSG).  
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Figure A-6 Enzymatic activity of purified GAPDH (1 µg/mL) as a function of increasing 
NaSH concentration. GAPDH was supplemented with NAD+ before treatment with 
NaSH. The addition of NAD+ did not change the effect of NaSH on GAPDH activity. 
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Figure A-7 MS/MS spectrum of GAPDH tryptic peptide (m/z 765.90) containing 
carbamidomethylated Cys 247, sequenced from reduced GAPDH sample (no NaSH or PS 
treatments). 
 
Figure A-8 MS/MS spectrum of GAPDH tryptic peptide (m/z 781.89) containing S-
sulfurated and carbamidomethylated Cys 247, sequenced from reduced and NaSH-treated 
GAPDH sample. 
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Figure A-9 MS/MS spectrum of GAPDH tryptic peptide (m/z 737.39) containing 
unlabeled Cys 247, sequenced from GSSG-treated GAPDH sample (no NaSH or PS 
treatments). 
 
Figure A-10 MS/MS spectrum of GAPDH tryptic peptide (m/z 889.92) containing 
glutathionylated Cys 247, sequenced from GSSG-treated GAPDH sample (no NaSH or 
PS treatments).   
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Figure A-11 MS/MS spectrum of GAPDH tryptic peptide (m/z 593.61) containing 
glutathionylated Cys 247, sequenced from GSSG-treated GAPDH sample (no NaSH or 
PS treatments). 
 
Figure A-12 MS/MS spectrum of GAPDH tryptic peptide (m/z 888.95) containing 
carbamidomethylated Cys 152 and free Cys 156, sequenced from GSSG and NaSH-
treated GAPDH sample.   
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Figure A-13 MS/MS spectrum of GAPDH tryptic peptide (m/z 799.91) containing NEM-
labeled Cys 247, indicating S-nitrosation of Cys 247, sequenced from GSNO-treated 
GAPDH sample subject to differential labeling. 
 
Figure A-14 MS/MS spectrum of GAPDH tryptic peptide (m/z 951.48) containing 
carbamidomethylated Cys 152 and NEM-labeled Cys 156, indicating S-nitrosation of Cys 
156, sequenced from GSNO-treated GAPDH sample subject to differential labeling. 
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Figure A-15 MS/MS spectrum of GAPDH tryptic peptide (m/z 985.49) containing NEM-
labeled Cys 152 and NEM-labeled Cys 156, indicating S-nitrosation of Cys 152 and Cys 
156, sequenced from GSNO-treated GAPDH sample subject to differential labeling. 
 
Figure A-16 MS/MS spectrum of C156S GAPDH tryptic peptide (m/z 852.45) 
containing free Cys 152, sequenced from C156S GAPDH sample (no NaSH or PS 
treatments). 
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Figure A-17 MS/MS spectrum of C156S GAPDH tryptic peptide (m/z 880.96) 
containing carbamidomethylated Cys 152, sequenced from C156S GAPDH sample (no 
NaSH or PS treatments). 
 
Figure A-18 MS/MS spectrum of C156S GAPDH tryptic peptide (m/z 896.95) 
containing S-sulfurated and carbamidomethylated Cys 152, sequenced from PS-treated 
C156S GAPDH sample. 
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Appendix B 
 
Figure B-1 PSD-MS spectrum of YVH1 peptide (m/z 937.96) from a 5 protein mixture 
enriched for sulfur-containing peptides by AuNPs. 
 
Figure B-2 PSD-MS spectrum of YVH1 peptide (m/z 966.36) from a 5 protein mixture 
enriched for sulfur-containing peptides by AuNPs. 
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Figure B-3 PSD-MS spectrum of YVH1 peptide (m/z 1183.16) from a 5 protein mixture 
enriched for sulfur-containing peptides by AuNPs. 
 
Figure B-4 PSD-MS spectrum of YVH1 peptide (m/z 1283.31) from a 5 protein mixture 
enriched for sulfur-containing peptides by AuNPs. 
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Figure B-5 PSD-MS spectrum of lysozyme peptide (m/z 1436.16) from a 5 protein 
mixture enriched for sulfur-containing peptides by AuNPs. 
 
Figure B-6 PSD-MS spectrum of PDI peptide (m/z 1537.41) from a 5 protein mixture 
enriched for sulfur-containing peptides by AuNPs. 
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Figure B-7 PSD-MS spectrum of lysozyme peptide (m/z 1677.65) from a 5 protein 
mixture enriched for sulfur-containing peptides by AuNPs. 
 
Figure B-8 PSD-MS spectrum of YVH1 peptide (m/z 1708.41) from a 5 protein mixture 
enriched for sulfur-containing peptides by AuNPs. 
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Figure B-9 PSD-MS spectrum of lysozyme peptide (m/z 1805.44) from a 5 protein 
mixture enriched for sulfur-containing peptides by AuNPs. 
 
Figure B-10 PSD-MS spectrum of BSA peptide (m/z 1825.68) from a 5 protein mixture 
enriched for sulfur-containing peptides by AuNPs. 
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Figure B-11 PSD-MS spectrum of PDI peptide (m/z 2419.85) from a 5 protein mixture 
enriched for sulfur-containing peptides by AuNPs. 
 
Figure B-12 PSD-MS spectrum of YVH1 peptide (m/z 2536.71) from a 5 protein 
mixture enriched for sulfur-containing peptides by AuNPs. 
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Figure B-13 PSD-MS spectrum of CSE peptide (m/z 2563.19) from a 5 protein mixture 
enriched for sulfur-containing peptides by AuNPs. 
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